<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="c3d774f4-3240-4803-bf7e-1712e302c83b"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use ZEPBOUND safely and effectively. See full prescribing information for ZEPBOUND.<br/>
      <br/>ZEPBOUND<sup>Â®</sup> (tirzepatide) Injection, for subcutaneous use<br/>Initial U.S. Approval: <content styleCode="bold">2022</content>
   </title>
   <effectiveTime value="20250312"/>
   <setId root="487cd7e7-434c-4925-99fa-aa80b1cc776b"/>
   <versionNumber value="18"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="006421325" root="1.3.6.1.4.1.519.1"/>
            <name>Eli Lilly and Company</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="dcl-dpl">
               <id root="793b89f4-514a-49a7-b34d-f6a19e883337"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250218"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-2506" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ZEPBOUND</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="2.5"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0002-2506-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-2506-80" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20231108"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-2506-61" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20231108"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231108"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217806" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-2495" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ZEPBOUND</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0002-2495-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-2495-80" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20231108"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231108"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217806" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-2484" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ZEPBOUND</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="7.5"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0002-2484-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-2484-80" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20231108"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231108"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217806" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-2471" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ZEPBOUND</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0002-2471-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-2471-80" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20231108"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231108"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217806" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-2460" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ZEPBOUND</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="12.5"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0002-2460-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-2460-80" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20231108"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231108"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217806" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-2457" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ZEPBOUND</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="15"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0002-2457-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-2457-80" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20231108"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231108"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217806" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-0152" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Zepbound</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="2.5"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-0152-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240328"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-0152-04" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240808"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231108"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217806" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-0243" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Zepbound</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-0243-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240328"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-0243-04" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240808"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231108"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217806" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-1214" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Zepbound</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="7.5"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-1214-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240328"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-1214-04" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250218"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231108"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217806" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-1340" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Zepbound</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-1340-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240328"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-1340-04" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250218"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231108"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217806" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-1423" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Zepbound</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="12.5"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-1423-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240328"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-1423-04" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20240808"/>
                                          <high value="20240808"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231108"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217806" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-2002" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Zepbound</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tirzepatide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="15"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tirzepatide</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OYN3CCI6QE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>tirzepatide</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.1"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="0.5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Phosphate, Dibasic, Heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-2002-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240328"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-2002-04" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20240808"/>
                                          <high value="20240808"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231108"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217806" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="07a56f45-7c1d-4e7d-aeb3-38401c350ce5"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20241220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="2.000%" align="left"/>
                           <col width="73.000%" align="left"/>
                           <col width="25.000%" align="left"/>
                           <tbody>
                              <tr>
                                 <td colspan="2" align="left" valign="top">Indications and Usage (<linkHtml href="#s3">1</linkHtml>)
</td>
                                 <td align="right" valign="top">12/2024
</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top">Dosage and Administration (<linkHtml href="#s7">2.2</linkHtml>)
</td>
                                 <td align="right" valign="top">12/2024
</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top">Warnings and Precautions
</td>
                                 <td align="right" valign="top"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top"/>
                                 <td align="left" valign="top">Pulmonary Aspiration During General Anesthesia or Deep Sedation (<linkHtml href="#s26">5.10</linkHtml>)
</td>
                                 <td align="right" valign="top">10/2024
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="b4337bef-e529-4ee7-b7c9-62cb5177d1f1"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: RISK OF THYROID C-CELL TUMORS
</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined
</content>
                        <content styleCode="bold italics">[see Warnings and Precautions (<linkHtml href="#s17">5.1</linkHtml>) and Nonclinical Toxicology (<linkHtml href="#s86">13.1</linkHtml>)].</content>
                     </item>
                     <item>
                        <content styleCode="bold">ZEPBOUND is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome typeÂ 2 (MENÂ 2)
</content>
                        <content styleCode="bold italics">[see Contraindications (<linkHtml href="#s15">4</linkHtml>)]</content>
                        <content styleCode="bold">. Counsel patients regarding the potential risk for MTC with the use of ZEPBOUND and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with ZEPBOUND
</content>
                        <content styleCode="bold italics">[see Contraindications (<linkHtml href="#s15">4</linkHtml>) and Warnings and Precautions (<linkHtml href="#s17">5.1</linkHtml>)].</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: RISK OF THYROID C-CELL TUMORS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">In rats, tirzepatide causes thyroid C-cell tumors. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined (<linkHtml href="#s17">5.1</linkHtml>, <linkHtml href="#s86">13.1</linkHtml>).</content>
                           </item>
                           <item>
                              <content styleCode="bold">ZEPBOUND is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome typeÂ 2 (MENÂ 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors (<linkHtml href="#s15">4</linkHtml>, <linkHtml href="#s17">5.1</linkHtml>).</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s3">
               <id root="e8c1d4bc-4d71-4c71-9e7f-20f1714109ef"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE
</title>
               <text>
                  <paragraph>ZEPBOUND<sup>Â®</sup> is indicated in combination with a reduced-calorie diet and increased physical activity:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.
</item>
                     <item>
                        <content styleCode="xmChange"/>to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
</item>
                  </list>
               </text>
               <effectiveTime value="20241220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ZEPBOUND<sup>Â®</sup> is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity:
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. (<linkHtml href="#s3">1</linkHtml>)
</item>
                           <item>to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. (<linkHtml href="#s3">1</linkHtml>)
</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use:</content>
                        </paragraph>
                        <paragraph>Coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. (<linkHtml href="#s3">1</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s4">
                     <id root="9aeaf840-a9b8-4d9d-bcc2-98d1b46dd30e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <paragraph>ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s5">
               <id root="f07ea842-970c-4171-943e-ac22c4e29bbe"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION
</title>
               <effectiveTime value="20241220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Recommended Dose Escalation Schedule</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended starting dosage is 2.5Â mg injected subcutaneously once weekly for 4 weeks. Increase the dosage in 2.5 mg increments after at least 4 weeks until recommended maintenance dosage is achieved. (<linkHtml href="#s6">2.1</linkHtml>)
</item>
                           <item>Consider treatment response and tolerability when selecting the maintenance dosage. (<linkHtml href="#s6">2.1</linkHtml>)
</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Recommended Maintenance and Maximum Dosage</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Weight Reduction and Long-Term Maintenance:</content> 5Â mg, 10Â mg, or 15Â mg injected subcutaneously once weekly. (<linkHtml href="#s7">2.2</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Obstructive Sleep Apnea:</content> 10Â mg or 15Â mg injected subcutaneously once weekly. (<linkHtml href="#s7">2.2</linkHtml>)
</item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">Maximum Recommended Dosage:</content> 15Â mg injected subcutaneously once weekly. (<linkHtml href="#s7">2.2</linkHtml>)
</paragraph>
                        <paragraph>
                           <content styleCode="underline">Administration Instructions</content>
                        </paragraph>
                        <paragraph>See full prescribing information for administration instructions. (<linkHtml href="#s13">2.4</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s6">
                     <id root="70ebef60-f4d3-4ca9-9959-411f31d83321"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dose Escalation Schedule
</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended starting dosage of ZEPBOUND for all indications is 2.5Â mg injected subcutaneously once weekly for 4Â weeks.
</item>
                           <item>The 2.5Â mg dosage is for treatment initiation and is not approved as a maintenance dosage.
</item>
                           <item>Follow the dosage escalation below for all indications to reduce the risk of gastrointestinal adverse reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s18">5.2</linkHtml>) and Adverse Reactions (<linkHtml href="#s28">6.1</linkHtml>)]</content>.
</item>
                           <item>After 4Â weeks, increase the dosage to 5Â mg injected subcutaneously once weekly. The dosage may be increased in 2.5Â mg increments, after at least 4Â weeks on the current dose <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s7">2.2</linkHtml>)]</content>.
</item>
                           <item>Consider treatment response and tolerability when selecting the maintenance dosage. If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s7">
                     <id root="449c0fdd-a4db-43b2-970a-e2e500b0f0bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Maintenance and Maximum Dosage
</title>
                     <effectiveTime value="20241220"/>
                     <component>
                        <section ID="s8">
                           <id root="72d61a34-7a55-47be-89cd-65fb0d5a5eec"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Recommended Maintenance Dosage</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                           <component>
                              <section ID="s9">
                                 <id root="f9f95482-2370-4c40-aeba-dd38256b4ad9"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Weight Reduction and Long-Term Maintenance</content>
                                    </paragraph>
                                    <paragraph>The recommended maintenance dosage is 5Â mg, 10Â mg, or 15Â mg, injected subcutaneously once weekly.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241220"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s10">
                                 <id root="92ed5654-f8a4-4903-89c2-079376c64f8b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="xmChange"/>
                                       <content styleCode="italics">OSA</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="xmChange"/>The recommended maintenance dosage is 10Â mg or 15Â mg injected subcutaneously once weekly.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241220"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s11">
                           <id root="0b392a6f-6b62-4902-b25c-9a868bebc9bc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Maximum Recommended Dosage</content>
                              </paragraph>
                              <paragraph>The maximum dosage of ZEPBOUND for all indications is 15Â mg injected subcutaneously once weekly.
</paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s12">
                     <id root="0a8f2ec9-7af2-40e8-8bd9-3870d57e65d2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Recommendations Regarding Missed Dose
</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>If a dose is missed, instruct patients to administer ZEPBOUND as soon as possible within 4Â days (96Â hours) after the missed dose. If more than 4Â days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.
</item>
                           <item>The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3Â days (72Â hours).
</item>
                        </list>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s13">
                     <id root="dcc76fb9-4d2c-4443-bfc1-6888b8115022"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Important Administration Instructions
</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Prior to initiation of ZEPBOUND, train patients and caregivers on proper injection technique. Refer to the accompanying Instructions for Use for complete administration instructions with illustrations.
</item>
                           <item>Instruct patients using the single-dose vial to use a syringe appropriate for dose administration (e.g., a 1Â mL syringe capable of measuring a 0.5Â mL dose).
</item>
                           <item>Inspect ZEPBOUND visually before use. It should appear clear and colorless to slightly yellow. Do not use ZEPBOUND if particulate matter or discoloration is seen.
</item>
                           <item>Administer ZEPBOUND in combination with a reduced-calorie diet and increased physical activity.
</item>
                           <item>Administer ZEPBOUND once weekly at any time of day, with or without meals.
</item>
                           <item>Inject ZEPBOUND subcutaneously in the abdomen, thigh, or upper arm.
</item>
                           <item>Rotate injection sites with each dose.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s14">
               <id root="82d7db40-4ace-466a-8cdb-40606503959d"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS
</title>
               <text>
                  <paragraph>Injection: Clear, colorless to slightly yellow solution in pre-filled single-dose pens or single-dose vials, each available in the following strengths:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>2.5Â mg/0.5Â mL
</item>
                     <item>5Â mg/0.5Â mL
</item>
                     <item>7.5Â mg/0.5Â mL
</item>
                     <item>10Â mg/0.5Â mL
</item>
                     <item>12.5Â mg/0.5Â mL
</item>
                     <item>15Â mg/0.5Â mL
</item>
                  </list>
               </text>
               <effectiveTime value="20241220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 2.5Â mg, 5Â mg, 7.5Â mg, 10Â mg, 12.5Â mg, or 15Â mg per 0.5Â mL in single-dose pen or single-dose vial (<linkHtml href="#s14">3</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s15">
               <id root="28ddeffa-0690-4ba4-91f5-4dcdfef285e0"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS
</title>
               <text>
                  <paragraph>ZEPBOUND is contraindicated in patients with:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>A personal or family history of MTC or in patients with MENÂ 2 <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s17">5.1</linkHtml>)]</content>.
</item>
                     <item>Known serious hypersensitivity to tirzepatide or any of the excipients in ZEPBOUND. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with tirzepatide <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s22">5.6</linkHtml>) and Adverse Reactions (<linkHtml href="#s48">6.2</linkHtml>)]</content>.
</item>
                  </list>
               </text>
               <effectiveTime value="20241220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome typeÂ 2 (<linkHtml href="#s15">4</linkHtml>)
</item>
                           <item>Known serious hypersensitivity to tirzepatide or any of the excipients in ZEPBOUND (<linkHtml href="#s15">4</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s16">
               <id root="1d4b0bf6-39f5-4ed3-8537-2e09774f1ae3"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS
</title>
               <effectiveTime value="20241220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Severe Gastrointestinal Adverse Reactions:</content> Use has been associated with gastrointestinal adverse reactions, sometimes severe. Has not been studied in patients with severe gastrointestinal disease and is not recommended in these patients. (<linkHtml href="#s18">5.2</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Acute Kidney Injury:</content> Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. (<linkHtml href="#s19">5.3</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Acute Gallbladder Disease:</content> Has been reported in clinical trials. If cholecystitis is suspected, gallbladder studies and clinical follow-up are indicated. (<linkHtml href="#s20">5.4</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Acute Pancreatitis:</content> Has been reported in clinical trials. Discontinue promptly if pancreatitis is suspected. (<linkHtml href="#s21">5.5</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Hypersensitivity Reactions:</content> Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported postmarketing with tirzepatide. If suspected, advise patients to promptly seek medical attention and discontinue ZEPBOUND. (<linkHtml href="#s22">5.6</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Hypoglycemia:</content> Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing dose of insulin or insulin secretagogue may be necessary. Inform all patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. (<linkHtml href="#s23">5.7</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Mellitus:</content> Has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Monitor patients with a history of diabetic retinopathy for progression. (<linkHtml href="#s24">5.8</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Suicidal Behavior and Ideation:</content> Monitor for depression or suicidal thoughts. Discontinue ZEPBOUND if symptoms develop. (<linkHtml href="#s25">5.9</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Pulmonary Aspiration During General Anesthesia or Deep Sedation:</content> Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedures. (<linkHtml href="#s26">5.10</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s17">
                     <id root="ffd38a8b-77e7-4885-8548-1571dc6a7bf6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Risk of Thyroid C-Cell Tumors
</title>
                     <text>
                        <paragraph>In rats, tirzepatide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) in a 2-year study at clinically relevant plasma exposures <content styleCode="italics">[see Nonclinical Toxicology (<linkHtml href="#s86">13.1</linkHtml>)]</content>. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including MTC, in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
</paragraph>
                        <paragraph>ZEPBOUND is contraindicated in patients with a personal or family history of MTC or in patients with MENÂ 2. Counsel patients regarding the potential risk for MTC with the use of ZEPBOUND and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).
</paragraph>
                        <paragraph>Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with ZEPBOUND. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values &gt;50Â ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s18">
                     <id root="b7ea4b35-e0b8-4800-84b5-772814ac5a44"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Severe Gastrointestinal Adverse Reactions
</title>
                     <text>
                        <paragraph>Use of ZEPBOUND has been associated with gastrointestinal adverse reactions, sometimes severe <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s28">6.1</linkHtml>)]</content>. In a pool of two ZEPBOUND clinical trials for weight reduction (Studies 1 and 2), severe gastrointestinal adverse reactions were reported more frequently among patients receiving ZEPBOUND (5Â mg 1.7%, 10Â mg 2.5%, 15Â mg 3.1%) than placebo (1%). Similar rates of severe gastrointestinal adverse reactions were observed in ZEPBOUND clinical trials for weight reduction and in ZEPBOUND clinical trials for OSA.
</paragraph>
                        <paragraph>ZEPBOUND has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s19">
                     <id root="50fc8296-a63b-488e-a2e1-bbb2c6461f93"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Acute Kidney Injury
</title>
                     <text>
                        <paragraph>Use of ZEPBOUND has been associated with acute kidney injury, which can result from dehydration due to gastrointestinal adverse reactions to ZEPBOUND, including nausea, vomiting, and diarrhea <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s28">6.1</linkHtml>)]</content>.
</paragraph>
                        <paragraph>In patients treated with GLP-1 receptor agonists, there have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis. Some of these events have been reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function in patients reporting adverse reactions to ZEPBOUND that could lead to volume depletion.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s20">
                     <id root="87976e89-65e6-4475-b8da-6b8fee580362"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Acute Gallbladder Disease
</title>
                     <text>
                        <paragraph>Treatment with ZEPBOUND and GLP-1 receptor agonists is associated with an increased occurrence of acute gallbladder disease.
</paragraph>
                        <paragraph>In a pool of two ZEPBOUND clinical trials for weight reduction (Studies 1 and 2), cholelithiasis was reported in 1.1% of ZEPBOUND-treated patients and 1% of placebo-treated patients, cholecystitis was reported in 0.7% of ZEPBOUND-treated patients and 0.2% of placebo-treated patients, and cholecystectomy was reported in 0.2% of ZEPBOUND-treated patients and no placebo-treated patients. Acute gallbladder events were associated with weight reduction. Similar rates of cholelithiasis were reported in ZEPBOUND clinical trials for weight reduction and in ZEPBOUND trials for OSA. If cholecystitis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s21">
                     <id root="73fd9ed5-a40a-40f6-8411-36e7516c64c6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Acute Pancreatitis
</title>
                     <text>
                        <paragraph>Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists or tirzepatide.
</paragraph>
                        <paragraph>In clinical trials of tirzepatide for a different indication, 14 events of acute pancreatitis were confirmed by adjudication in 13 tirzepatide-treated patients (0.23 patients per 100Â years of exposure) versus 3 events in 3 comparator-treated patients (0.11 patients per 100Â years of exposure). In a pool of two ZEPBOUND clinical trials for weight reduction (Studies 1 and 2), 0.2% of ZEPBOUND-treated patients had acute pancreatitis confirmed by adjudication (0.14 patients per 100Â years of exposure) versus 0.2% of placebo-treated patients (0.15 patients per 100Â years of exposure). The exposure-adjusted incidence rate for treatment-emergent adjudication-confirmed pancreatitis in the pooled clinical studies for OSA (Studies 5 and 6) was 0.84 patients per 100Â years for ZEPBOUND and 0 for placebo-treated patients.
</paragraph>
                        <paragraph>After initiation of ZEPBOUND, observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by vomiting). If pancreatitis is suspected, discontinue ZEPBOUND and initiate appropriate management. Continuation of ZEPBOUND after a confirmed diagnosis of pancreatitis should be individually determined in the clinical judgment of a patient's health care provider.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s22">
                     <id root="2eeb19de-5cc8-4fe9-bb1b-787ead8e712b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Hypersensitivity Reactions
</title>
                     <text>
                        <paragraph>There have been postmarketing reports of serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) in patients treated with tirzepatide. In a pool of two ZEPBOUND clinical studies for weight reduction (Studies 1 and 2), 0.1% of ZEPBOUND-treated patients had severe hypersensitivity reactions compared to no placebo-treated patients. Similar rates of severe hypersensitivity reactions were observed in ZEPBOUND clinical trials for weight reduction and in ZEPBOUND trials for OSA. If hypersensitivity reactions occur, advise patients to promptly seek medical attention and discontinue use of ZEPBOUND. Do not use in patients with a previous serious hypersensitivity reaction to tirzepatide or any of the excipients in ZEPBOUND <content styleCode="italics">[see Contraindications (<linkHtml href="#s15">4</linkHtml>) and Adverse Reactions (<linkHtml href="#s48">6.2</linkHtml>)]</content>.
</paragraph>
                        <paragraph>Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with GLP-1 receptor agonists. Use caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to these reactions with ZEPBOUND.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s23">
                     <id root="e5848e77-9068-4ebb-a727-65d4719a4efd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Hypoglycemia
</title>
                     <text>
                        <paragraph>ZEPBOUND lowers blood glucose and can cause hypoglycemia.
</paragraph>
                        <paragraph>In a trial of patients with typeÂ 2 diabetes mellitus and BMI â¥27Â kg/m<sup>2</sup> (Study 2), hypoglycemia (plasma glucose &lt;54Â mg/dL) was reported in 4.2% of ZEPBOUND-treated patients versus 1.3% of placebo-treated patients. In this trial, patients taking ZEPBOUND in combination with an insulin secretagogue (e.g., sulfonylurea) had increased risk of hypoglycemia (10.3%) compared to ZEPBOUND-treated patients not taking a sulfonylurea (2.1%). There is also increased risk of hypoglycemia in patients treated with tirzepatide in combination with insulin <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s50">7.1</linkHtml>)]</content>.
</paragraph>
                        <paragraph>Hypoglycemia has also been associated with ZEPBOUND and GLP-1 receptor agonists in adults without typeÂ 2 diabetes mellitus <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s28">6.1</linkHtml>)]</content>.
</paragraph>
                        <paragraph>Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. In patients with diabetes mellitus, monitor blood glucose prior to starting ZEPBOUND and during ZEPBOUND treatment. The risk of hypoglycemia may be lowered by a reduction in the dose of insulin or sulfonylurea (or other concomitantly administered insulin secretagogue).
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s24">
                     <id root="72f2bd0b-75cd-415e-8539-51e3da5552cb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Diabetic Retinopathy Complications in Patients with TypeÂ 2 Diabetes Mellitus
</title>
                     <text>
                        <paragraph>Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Tirzepatide has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s25">
                     <id root="f2297106-dd18-451d-be71-8125bce555e0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Suicidal Behavior and Ideation
</title>
                     <text>
                        <paragraph>Suicidal behavior and ideation have been reported in clinical trials with other weight management products. Monitor patients treated with ZEPBOUND for the emergence or worsening of depression, suicidal thoughts or behaviors, and/or any unusual changes in mood or behavior. Discontinue ZEPBOUND in patients who experience suicidal thoughts or behaviors. Avoid ZEPBOUND in patients with a history of suicidal attempts or active suicidal ideation.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s26">
                     <id root="8fb872a6-9304-4899-be91-abb70db19537"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange"/>5.10 Pulmonary Aspiration During General Anesthesia or Deep Sedation
</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>ZEPBOUND delays gastric emptying <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s72">12.2</linkHtml>)]</content>. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations.
</paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking ZEPBOUND, including whether modifying preoperative fasting recommendations or temporarily discontinuing ZEPBOUND could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking ZEPBOUND.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s27">
               <id root="d638b096-a4f6-4539-a101-fbc6552c6235"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS
</title>
               <text>
                  <paragraph>The following serious adverse reactions are described below or elsewhere in the prescribing information:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Risk of Thyroid C-cell Tumors <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s17">5.1</linkHtml>)]</content>
                     </item>
                     <item>Severe Gastrointestinal Adverse Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s18">5.2</linkHtml>)]</content>
                     </item>
                     <item>Acute Kidney Injury <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s19">5.3</linkHtml>)]</content>
                     </item>
                     <item>Acute Gallbladder Disease <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s20">5.4</linkHtml>)]</content>
                     </item>
                     <item>Acute Pancreatitis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s21">5.5</linkHtml>)]</content>
                     </item>
                     <item>Hypersensitivity Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s22">5.6</linkHtml>)]</content>
                     </item>
                     <item>Hypoglycemia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s23">5.7</linkHtml>)]</content>
                     </item>
                     <item>Diabetic Retinopathy Complications in Patients with TypeÂ 2 Diabetes Mellitus <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s24">5.8</linkHtml>)]</content>
                     </item>
                     <item>Suicidal Behavior and Ideation <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s25">5.9</linkHtml>)]</content>
                     </item>
                     <item>Pulmonary Aspiration During General Anesthesia or Deep Sedation <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s26">5.10</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions, reported in â¥5% of patients treated with ZEPBOUND are: nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, gastroesophageal reflux disease. (<linkHtml href="#s28">6.1</linkHtml>)
</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s28">
                     <id root="4d046ef7-f9bf-4f23-9a21-c5886fffc92b"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience
</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                     <component>
                        <section ID="s29">
                           <id root="16f891d7-6c66-4c26-8d5d-fbe1fdcd2bde"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions in Patients for Weight Reduction and Long-Term Maintenance</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                           <component>
                              <section ID="s30">
                                 <id root="4f8badc7-36b2-41f0-a263-b1f8d72e3b68"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pool of Placebo</content>
                                       <content styleCode="italics">-</content>
                                       <content styleCode="italics">Controlled Weight Reduction Trials in Adults with Obesity or Overweight, with or without Type</content>Â <content styleCode="italics">2 Diabetes (Study 1 and Study 2)</content>
                                    </paragraph>
                                    <paragraph>ZEPBOUND was evaluated for safety in a pool of two randomized, double-blind, placebo-controlled trials that included 2,519 adult patients with obesity or overweight treated with ZEPBOUND for up to 72Â weeks and a 4-week off drug follow-up period (Study 1 and Study 2) <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s88">14.1</linkHtml>)]</content>. The mean age of patients was 47Â years and 37% were male. The population was 72% White, 12% Asian, 8% Black or African American, and 7% American Indian or Alaska Native; 51% identified as Hispanic or Latino ethnicity. Baseline characteristics included an average BMI of 37.4Â kg/m<sup>2</sup>, 29% with a BMI â¥40Â kg/m<sup>2</sup>, 41% with hypertension, 37% with dyslipidemia, 25% with typeÂ 2 diabetes mellitus, 7% with obstructive sleep apnea, and 4% with cardiovascular disease.
</paragraph>
                                    <paragraph>Across both trials, 4.8%, 6.3%, and 6.7% of patients treated with 5Â mg, 10Â mg, and 15Â mg of ZEPBOUND, respectively, permanently discontinued treatment as a result of adverse reactions compared to 3.4% of patients treated with placebo. The majority of patients who discontinued ZEPBOUND due to adverse reactions did so during the first few months of treatment due to gastrointestinal adverse reactions.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241220"/>
                                 <component>
                                    <section ID="s31">
                                       <id root="f0e3e650-b407-4781-83af-342a270ee005"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics underline">Common Adverse Reactions</content>
                                          </paragraph>
                                          <paragraph>
                                             <linkHtml href="#t1">TableÂ 1</linkHtml> shows common adverse reactions associated with the use of ZEPBOUND in the pool of two placebo-controlled trials for weight reduction (Study 1 and Study 2). These adverse reactions occurred more commonly with ZEPBOUND than with placebo and occurred in at least 2% of patients treated with ZEPBOUND.
</paragraph>
                                          <table ID="t1" width="100%">
                                             <caption>Table 1: Adverse Reactions (â¥2% and Greater than Placebo) in ZEPBOUND-Treated Adults with Obesity or Overweight in Weight Reduction and Long-term Maintenance Trials (Study 1 and Study 2)
</caption>
                                             <col width="30.826%" align="left"/>
                                             <col width="17.223%" align="left"/>
                                             <col width="17.243%" align="left"/>
                                             <col width="17.243%" align="left"/>
                                             <col width="17.463%" align="left"/>
                                             <tfoot>
                                                <tr>
                                                   <td colspan="5" align="left" valign="top">
                                                      <paragraph styleCode="footnote">
                                                         <sup>a</sup> Includes diarrhea, frequent bowel movements.
</paragraph>
                                                   </td>
                                                </tr>
                                                <tr>
                                                   <td colspan="5" align="left" valign="top">
                                                      <paragraph styleCode="footnote">
                                                         <sup>b</sup> Includes constipation, feces hard.
</paragraph>
                                                   </td>
                                                </tr>
                                                <tr>
                                                   <td colspan="5" align="left" valign="top">
                                                      <paragraph styleCode="footnote">
                                                         <sup>c</sup> Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness.
</paragraph>
                                                   </td>
                                                </tr>
                                                <tr>
                                                   <td colspan="5" align="left" valign="top">
                                                      <paragraph styleCode="footnote">
                                                         <sup>d</sup> Includes multiple related adverse event terms, such as injection site bruising, injection site erythema, injection site pruritus, injection site pain, injection site rash, injection site reaction.
</paragraph>
                                                   </td>
                                                </tr>
                                                <tr>
                                                   <td colspan="5" align="left" valign="top">
                                                      <paragraph styleCode="footnote">
                                                         <sup>e</sup> Includes asthenia, fatigue, lethargy, malaise.
</paragraph>
                                                   </td>
                                                </tr>
                                                <tr>
                                                   <td colspan="5" align="left" valign="top">
                                                      <paragraph styleCode="footnote">
                                                         <sup>f</sup> Includes blood pressure decreased, hypotension, orthostatic hypotension.
</paragraph>
                                                   </td>
                                                </tr>
                                             </tfoot>
                                             <tbody>
                                                <tr>
                                                   <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                                      <content styleCode="bold">
                                                         <br/>
                                                         <br/>
                                                         <br/>
                                                      </content>
                                                      <content styleCode="bold">Adverse Reaction</content>
                                                   </td>
                                                   <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                      <content styleCode="bold">
                                                         <br/>
                                                      </content>
                                                      <content styleCode="bold">Placebo<br/>(N=958)<br/>%</content>
                                                   </td>
                                                   <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                      <content styleCode="bold">ZEPBOUND<br/>5Â mg<br/>(N=630)<br/>%</content>
                                                   </td>
                                                   <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                      <content styleCode="bold">ZEPBOUND<br/>10Â mg<br/>(N=948)<br/>%</content>
                                                   </td>
                                                   <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                      <content styleCode="bold">ZEPBOUND<br/>15Â mg<br/>(N=941)<br/>%</content>
                                                   </td>
                                                </tr>
                                                <tr>
                                                   <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Nausea
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">8
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">25
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">29
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">28
</td>
                                                </tr>
                                                <tr>
                                                   <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Diarrhea<sup>a</sup>
                                                   </td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">8
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">19
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">21
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">23
</td>
                                                </tr>
                                                <tr>
                                                   <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Vomiting
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">2
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">8
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">11
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">13
</td>
                                                </tr>
                                                <tr>
                                                   <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Constipation<sup>b</sup>
                                                   </td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">17
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">14
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">11
</td>
                                                </tr>
                                                <tr>
                                                   <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Abdominal Pain<sup>c</sup>
                                                   </td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">9
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">9
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">10
</td>
                                                </tr>
                                                <tr>
                                                   <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Dyspepsia
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">4
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">9
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">9
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">10
</td>
                                                </tr>
                                                <tr>
                                                   <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Injection Site Reactions<sup>d</sup>
                                                   </td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">2
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">6
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">8
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">8
</td>
                                                </tr>
                                                <tr>
                                                   <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Fatigue<sup>e</sup>
                                                   </td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">3
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">6
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">7
</td>
                                                </tr>
                                                <tr>
                                                   <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Hypersensitivity Reactions
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">3
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                                </tr>
                                                <tr>
                                                   <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Eructation
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">1
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">4
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                                </tr>
                                                <tr>
                                                   <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Hair Loss
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">1
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">4
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                                </tr>
                                                <tr>
                                                   <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Gastroesophageal Reflux Disease
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">2
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">4
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">4
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                                </tr>
                                                <tr>
                                                   <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Flatulence
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">2
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">3
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">3
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">4
</td>
                                                </tr>
                                                <tr>
                                                   <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Abdominal Distension
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">2
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">3
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">3
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">4
</td>
                                                </tr>
                                                <tr>
                                                   <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Dizziness
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">2
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">4
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">4
</td>
                                                </tr>
                                                <tr>
                                                   <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Hypotension<sup>f</sup>
                                                   </td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">1
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">1
</td>
                                                   <td align="center" valign="top" styleCode="Botrule Rrule">2
</td>
                                                </tr>
                                             </tbody>
                                          </table>
                                          <paragraph>In a clinical trial for weight reduction that included an intensive lifestyle intervention lead-in period (Study 3), 287 patients were treated with ZEPBOUND for up to 72Â weeks. In a randomized withdrawal trial (Study 4), 783 patients were treated with ZEPBOUND for up to 36Â weeks, and 335 of these patients were treated for up to 88Â weeks <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s88">14.1</linkHtml>)]</content>. In Study 3, 10% of ZEPBOUND-treated patients and 2% of placebo-treated patients discontinued drug due to adverse reactions. In Study 4, 7% of patients discontinued ZEPBOUND treatment before randomized withdrawal at Week 36 due to adverse reactions. In Study 3 and Study 4, adverse reactions were similar to those reported in the two pooled ZEPBOUND clinical trials (Study 1 and Study 2).
</paragraph>
                                       </text>
                                       <effectiveTime value="20241220"/>
                                       <component>
                                          <section ID="s32">
                                             <id root="ad457067-17fc-4f18-a023-8eb15f99e874"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Gastrointestinal Adverse Reactions</content>
                                                </paragraph>
                                                <paragraph>In a pool of Study 1 and 2, gastrointestinal adverse reactions occurred more frequently among patients receiving ZEPBOUND (5Â mg 56%, 10Â mg 56%, 15Â mg 56%) than placebo (30%). More patients receiving ZEPBOUND 5Â mg (1.9%), ZEPBOUND 10Â mg (3.3%), and ZEPBOUND 15Â mg (4.3%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.5%). The majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time.
</paragraph>
                                             </text>
                                             <effectiveTime value="20241220"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section ID="s33">
                                             <id root="002622ad-dc05-4ddd-be4d-c2f2ae0a00d3"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Hypotension</content>
                                                </paragraph>
                                                <paragraph>In a pool of Study 1 and 2, hypotension occurred more frequently among patients taking ZEPBOUND (1.6%) than patients taking placebo (0.1%). Hypotension was more frequently seen in ZEPBOUND-treated patients on concomitant antihypertensive therapy (2.2%) compared to ZEPBOUND-treated patients not on antihypertensive therapy (1.2%). Hypotension also occurred in association with gastrointestinal adverse events and dehydration.
</paragraph>
                                             </text>
                                             <effectiveTime value="20241220"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section ID="s34">
                                             <id root="52b726bc-3148-4218-b390-aaaac27552b6"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Hypersensitivity Reactions</content>
                                                </paragraph>
                                                <paragraph>In a pool of Study 1 and 2, immediate hypersensitivity reactions (within one day after drug administration) occurred in 2.1% of ZEPBOUND-treated patients compared to 0.4% of placebo-treated patients, while non-immediate hypersensitivity reactions occurred in 3.5% of ZEPBOUND-treated patients compared to 2.7% of placebo-treated patients. Among ZEPBOUND-treated patients, hypersensitivity reactions were more frequent in those with anti-tirzepatide antibodies (6.2%) compared to those who did not develop anti-tirzepatide antibodies (3%) <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s84">12.6</linkHtml>)]</content>. The majority of the hypersensitivity reactions in trials were skin reactions (e.g., rash, itching).
</paragraph>
                                             </text>
                                             <effectiveTime value="20241220"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section ID="s35">
                                             <id root="c00cf4e6-d053-4845-b29c-de683c8a7e25"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Injection Site Reactions</content>
                                                </paragraph>
                                                <paragraph>In ZEPBOUND-treated patients in a pool of Study 1 and 2, injection site reactions were more frequent in those with anti-tirzepatide antibodies (11.3%) compared to those who did not develop anti-tirzepatide antibodies (1%) <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s84">12.6</linkHtml>)]</content>.
</paragraph>
                                             </text>
                                             <effectiveTime value="20241220"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section ID="s36">
                                             <id root="e2604564-6ba4-4807-9e1a-8c8c23870b34"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Hair Loss</content>
                                                </paragraph>
                                                <paragraph>Hair loss adverse reactions in ZEPBOUND-treated patients were associated with weight reduction. In a pool of Study 1 and 2, hair loss was reported more frequently in female than male patients in the ZEPBOUND (7.1% female versus 0.5% male) and placebo (1.3% female versus 0% male) treatment groups. No ZEPBOUND-treated patients and one placebo-treated patient discontinued study treatment due to hair loss.
</paragraph>
                                             </text>
                                             <effectiveTime value="20241220"/>
                                          </section>
                                       </component>
                                    </section>
                                 </component>
                                 <component>
                                    <section ID="s37">
                                       <id root="a618f85b-ff4e-4e70-9852-697ddf0e8d67"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics underline">Other Adverse Reactions</content>
                                          </paragraph>
                                       </text>
                                       <effectiveTime value="20241220"/>
                                       <component>
                                          <section ID="s38">
                                             <id root="d66cf670-e53d-4539-b90b-100e64303372"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Acute Kidney Injury</content>
                                                </paragraph>
                                                <paragraph>In a pool of Study 1 and 2, acute kidney injury was reported in 0.5% of ZEPBOUND-treated patients compared to 0.2% of placebo-treated patients.
</paragraph>
                                             </text>
                                             <effectiveTime value="20241220"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section ID="s39">
                                             <id root="c02b17d9-797e-4349-af3e-1498b35b1ba2"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Acute Gallbladder Disease</content>
                                                </paragraph>
                                                <paragraph>In a pool of Study 1 and 2, cholelithiasis was reported in 1.1% of ZEPBOUND-treated patients and 1% of placebo-treated patients, cholecystitis was reported in 0.7% of ZEPBOUND-treated patients and 0.2% of placebo-treated patients, and cholecystectomy was reported in 0.2% of ZEPBOUND-treated patients and no placebo-treated patients.
</paragraph>
                                             </text>
                                             <effectiveTime value="20241220"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section ID="s40">
                                             <id root="75ca9709-7f42-44c9-84a6-37697817ad16"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Hypoglycemia</content>
                                                </paragraph>
                                                <paragraph>In Study 2, a trial of patients with typeÂ 2 diabetes mellitus and BMI â¥27Â kg/m<sup>2</sup>, hypoglycemia (plasma glucose &lt;54Â mg/dL) was reported in 4.2% of ZEPBOUND-treated patients versus 1.3% of placebo-treated patients.
</paragraph>
                                                <paragraph>In Study 1, a trial of ZEPBOUND in adults with obesity/overweight without typeÂ 2 diabetes mellitus, there was no systematic capturing of hypoglycemia, but plasma glucose &lt;54Â mg/dL was reported in 0.3% of ZEPBOUND-treated patients versus no placebo-treated patients.
</paragraph>
                                             </text>
                                             <effectiveTime value="20241220"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section ID="s41">
                                             <id root="b99c56cb-6d2c-4c1d-9c02-9e60ea2c316a"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Heart Rate Increase</content>
                                                </paragraph>
                                                <paragraph>In a pool of Study 1 and 2, treatment with ZEPBOUND resulted in a mean increase in heart rate of 1 to 3Â beats per minute compared to no increase in placebo-treated patients.
</paragraph>
                                             </text>
                                             <effectiveTime value="20241220"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section ID="s42">
                                             <id root="d06ab9d9-b58b-4e7b-bfb4-9b7925bc746b"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Dysesthesia</content>
                                                </paragraph>
                                                <paragraph>In a pool of Study 1 and 2, dysesthesia occurred more frequently among patients receiving ZEPBOUND (5Â mg 0.2%, 10Â mg 0.2%, 15Â mg 0.4%) than placebo (0.1%).
</paragraph>
                                             </text>
                                             <effectiveTime value="20241220"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section ID="s43">
                                             <id root="825b8e35-458a-4f21-83a2-566af29ad764"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Dysgeusia</content>
                                                </paragraph>
                                                <paragraph>In a pool of Study 1 and 2, dysgeusia was reported by 0.4% of ZEPBOUND-treated patients and no placebo-treated patients.
</paragraph>
                                             </text>
                                             <effectiveTime value="20241220"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section ID="s44">
                                             <id root="242a4bdb-9abb-422b-b72a-6df8e1f76d73"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Dry Mouth</content>
                                                </paragraph>
                                                <paragraph>In a pool of Study 1 and 2, dry mouth or dry throat was reported by 1% of ZEPBOUND-treated patients and 0.1% of placebo-treated patients.
</paragraph>
                                             </text>
                                             <effectiveTime value="20241220"/>
                                          </section>
                                       </component>
                                    </section>
                                 </component>
                                 <component>
                                    <section ID="s45">
                                       <id root="74dedec6-1644-464a-bd87-255664b6d422"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics underline">Laboratory Abnormalities</content>
                                          </paragraph>
                                       </text>
                                       <effectiveTime value="20241220"/>
                                       <component>
                                          <section ID="s46">
                                             <id root="0a67be2a-bf3a-46b9-a6dd-cc5ca2074aa7"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Amylase and Lipase Increase</content>
                                                </paragraph>
                                                <paragraph>In a pool of Study 1 and 2, treatment with ZEPBOUND resulted in mean increases from baseline in serum pancreatic amylase concentrations of 20% to 25% and serum lipase concentrations of 28% to 35%, compared to mean increases from baseline in pancreatic amylase of 2.1% and serum lipase of 5.8% in placebo-treated patients. The clinical significance of elevations in amylase or lipase with ZEPBOUND is unknown in the absence of other signs and symptoms of pancreatitis.
</paragraph>
                                             </text>
                                             <effectiveTime value="20241220"/>
                                          </section>
                                       </component>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s47">
                           <id root="9d552f17-2911-478e-bd0a-e93d487da859"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions in Patients with Obstructive Sleep Apnea</content>
                              </paragraph>
                              <paragraph>ZEPBOUND was evaluated in 2 randomized, double-blind, placebo-controlled trials (Study 5 and Study 6) that included a total of 467 adult patients with moderate to severe OSA and obesity <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s98">14.2</linkHtml>)]</content>. Study 5 enrolled 234 patients who were unable or unwilling to use Positive Airway Pressure (PAP) therapy and Study 6 enrolled 235 patients who were on PAP therapy. The adverse reactions observed with ZEPBOUND 10Â mg or 15Â mg administered subcutaneously once weekly were similar to those reported in the two pooled placebo controlled clinical trials for weight reduction (Study 1 and Study 2).
</paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s48">
                     <id root="4249cab3-e6b0-4aac-a0e6-2572a40a3ec7"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience
</title>
                     <text>
                        <paragraph>The following adverse reactions have been reported during post-approval use of tirzepatide, the active ingredient in ZEPBOUND. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure.
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hypersensitivity:</content> anaphylaxis, angioedema
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal:</content> ileus
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pulmonary:</content> Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s49">
               <id root="bde5e32f-a5e2-4b65-8149-bbdbbc199cec"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS
</title>
               <effectiveTime value="20241220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ZEPBOUND delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. (<linkHtml href="#s51">7.2</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s50">
                     <id root="8e574aeb-b9a8-48bc-a52c-df8801571861"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Concomitant Use with Insulin or an Insulin Secretagogue (e.g., Sulfonylurea)
</title>
                     <text>
                        <paragraph>ZEPBOUND lowers blood glucose. When initiating ZEPBOUND, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (e.g., sulfonylureas) to reduce the risk of hypoglycemia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s23">5.7</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s51">
                     <id root="50295876-82d3-42e9-a70c-879cd03bbc46"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Oral Medications
</title>
                     <text>
                        <paragraph>ZEPBOUND delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with ZEPBOUND.
</paragraph>
                        <paragraph>Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with ZEPBOUND.
</paragraph>
                        <paragraph>Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception, for 4Â weeks after initiation with ZEPBOUND and for 4Â weeks after each dose escalation. Hormonal contraceptives that are not administered orally should not be affected <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s62">8.3</linkHtml>) and Clinical Pharmacology (<linkHtml href="#s72">12.2</linkHtml>, <linkHtml href="#s73">12.3</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s52">
               <id root="a8159f78-03a2-446b-a747-b05a030959bb"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS
</title>
               <effectiveTime value="20241220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Pregnancy:</content> May cause fetal harm. When pregnancy is recognized, discontinue ZEPBOUND. (<linkHtml href="#s53">8.1</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Females of Reproductive Potential:</content> Advise females using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4Â weeks after initiation and for 4Â weeks after each dose escalation. (<linkHtml href="#s62">8.3</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s53">
                     <id root="350b45bd-9959-44cb-87ef-962b5b93c75d"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy
</title>
                     <effectiveTime value="20241220"/>
                     <component>
                        <section ID="s54">
                           <id root="805289c2-2c38-46aa-b326-a79dee2bf0ec"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Exposure Registry</content>
                              </paragraph>
                              <paragraph>There will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ZEPBOUND (tirzepatide) during pregnancy. Pregnant patients exposed to ZEPBOUND and healthcare providers are encouraged to contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).
</paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s55">
                           <id root="2686586b-5895-4575-a782-e3e7c1b9c13a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Weight loss offers no benefit to a pregnant patient and may cause fetal harm. Advise pregnant patients that weight loss is not recommended during pregnancy and to discontinue ZEPBOUND when a pregnancy is recognized <content styleCode="italics">(see Clinical Considerations)</content>. Available data with tirzepatide in pregnant patients are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide during pregnancy.
</paragraph>
                              <paragraph>In pregnant rats administered tirzepatide during organogenesis, fetal growth reductions and fetal abnormalities occurred at clinical exposure in maternal rats based on AUC. In rabbits administered tirzepatide during organogenesis, fetal growth reductions were observed at clinically relevant exposures based on AUC. These adverse embryo/fetal effects in animals coincided with pharmacological effects on maternal weight and food consumption <content styleCode="italics">(see Data)</content>.
</paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is increased when compared to the general population. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
</paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s56">
                           <id root="66fe89d4-0b4f-4c50-8f59-8252c7d1704d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                           <component>
                              <section ID="s57">
                                 <id root="51fb6981-1a9c-4abd-b950-0df855c29b8b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Disease-Associated Maternal and/or Embryo/Fetal Risk</content>
                                    </paragraph>
                                    <paragraph>Appropriate weight gain based on pre-pregnancy weight is currently recommended for all pregnant patients, including those with obesity or overweight, due to the obligatory weight gain that occurs in maternal tissues during pregnancy.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241220"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s58">
                           <id root="3387db9b-8310-47c4-87ee-225e1ea820b1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                           <component>
                              <section ID="s59">
                                 <id root="62e59988-b41a-4b40-96c9-5d2db81e76f0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>In pregnant rats given twice weekly subcutaneous doses of 0.02, 0.1, and 0.5Â mg/kg tirzepatide [0.03-, 0.07-, and 0.5-fold the maximum recommended human dose (MRHD) of 15Â mg once weekly based on AUC] during organogenesis, increased incidences of external, visceral, and skeletal malformations, increased incidences of visceral and skeletal developmental variations, and decreased fetal weights coincided with pharmacologically-mediated reductions in maternal body weights and food consumption at 0.5Â mg/kg. In pregnant rabbits given once weekly subcutaneous doses of 0.01, 0.03, or 0.1Â mg/kg tirzepatide (0.01-, 0.06-, and 0.2-fold the MRHD) during organogenesis, pharmacologically mediated effects on the gastrointestinal system resulting in maternal mortality or abortion in a few rabbits occurred at all dose levels. Reduced fetal weights associated with decreased maternal food consumption and body weights were observed at 0.1Â mg/kg. In a pre- and post-natal study in rats administered subcutaneous doses of 0.02, 0.10, or 0.25Â mg/kg tirzepatide twice weekly from implantation through lactation, F<sub>1</sub> pups from F<sub>0</sub> maternal rats given 0.25Â mg/kg tirzepatide had statistically significant lower mean body weight when compared to controls from post-natal day 7 through post-natal day 126 for males and post-natal day 56 for females.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241220"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s60">
                     <id root="ce213002-f0cc-4f19-8c1e-8c1395aa8ef6"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation
</title>
                     <effectiveTime value="20241220"/>
                     <component>
                        <section ID="s61">
                           <id root="5eb34695-21f7-47ed-9be2-650300fcd9d5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on the presence of tirzepatide or its metabolites in animal or human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ZEPBOUND and any potential adverse effects on the breastfed infant from ZEPBOUND or from the underlying maternal condition.
</paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s62">
                     <id root="f91da107-0fbe-47e5-8a8c-5c4f624e2a6c"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential
</title>
                     <effectiveTime value="20241220"/>
                     <component>
                        <section ID="s63">
                           <id root="d2c126e8-dd42-47b0-b087-b25b2d0c03e8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                              <paragraph>Use of ZEPBOUND may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception, for 4Â weeks after initiation with ZEPBOUND and for 4Â weeks after each dose escalation <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s51">7.2</linkHtml>) and Clinical Pharmacology (<linkHtml href="#s72">12.2</linkHtml>, <linkHtml href="#s73">12.3</linkHtml>)]</content>.
</paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s64">
                     <id root="5508ed83-8bc1-4212-874a-1d7e38edf9e5"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use
</title>
                     <text>
                        <paragraph>The safety and effectiveness of ZEPBOUND have not been established in pediatric patients.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s65">
                     <id root="78b53cf8-2f7e-4739-801f-9aba743c7ffc"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use
</title>
                     <text>
                        <paragraph>In a pool of two fixed dose ZEPBOUND clinical studies for weight reduction (Study 1 and Study 2), 226 (9%) ZEPBOUND-treated patients were 65Â years of age or older, and 13 (0.5%) ZEPBOUND-treated patients were 75Â years of age or older at baseline.
</paragraph>
                        <paragraph>No overall differences in safety or effectiveness of ZEPBOUND have been observed between patients 65Â years of age and older and younger adult patients.
</paragraph>
                        <paragraph>ZEPBOUND clinical studies in OSA (Study 5 and Study 6) did not include sufficient numbers of patients age 65Â years or older to determine whether they respond differently from younger adult patients. Other reported clinical experience with tirzepatide has not identified differences in responses between the elderly and younger patients.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s66">
                     <id root="f4380c80-fbde-4f9f-9648-f0dc35742a79"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment
</title>
                     <text>
                        <paragraph>No dosage adjustment of ZEPBOUND is recommended for patients with renal impairment. In subjects with renal impairment including end-stage renal disease (ESRD), no change in tirzepatide pharmacokinetics (PK) was observed <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s73">12.3</linkHtml>)]</content>. Monitor renal function in patients reporting adverse reactions to ZEPBOUND that could lead to volume depletion <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s19">5.3</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s67">
                     <id root="b1e7883c-b8df-42c0-9f2a-ce87dcec990e"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Hepatic Impairment
</title>
                     <text>
                        <paragraph>No dosage adjustment of ZEPBOUND is recommended for patients with hepatic impairment. In a clinical pharmacology study in subjects with varying degrees of hepatic impairment, no change in tirzepatide PK was observed <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s73">12.3</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s68">
               <id root="a7d9160c-8be4-48a0-8a6e-3833511bed77"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE
</title>
               <text>
                  <paragraph>In the event of an overdosage, contact the Poison Help Line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations. Appropriate supportive treatment should be initiated according to the patient's clinical signs and symptoms. A period of observation and treatment for these symptoms may be necessary, taking into account the half-life of tirzepatide of approximately 5Â days.
</paragraph>
               </text>
               <effectiveTime value="20241220"/>
            </section>
         </component>
         <component>
            <section ID="s69">
               <id root="cfbda606-8c24-46d8-b4a4-061ca1cf3a9f"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION
</title>
               <text>
                  <paragraph>ZEPBOUND (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53Â Da and the empirical formula is C<sub>225</sub>H<sub>348</sub>N<sub>48</sub>O<sub>68</sub>.
</paragraph>
                  <paragraph>Structural formula:
</paragraph>
                  <renderMultiMedia ID="f01" referencedObject="mm01"/>
                  <paragraph>ZEPBOUND is a clear, colorless to slightly yellow, sterile solution for subcutaneous use. Each single-dose pen or single-dose vial contains preservative-free 0.5Â mL solution of 2.5Â mg, 5Â mg, 7.5Â mg, 10Â mg, 12.5Â mg, or 15Â mg of tirzepatide and the following excipients: sodium chloride (4.1Â mg), sodium phosphate dibasic heptahydrate (0.7Â mg), and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH. ZEPBOUND has a pH of 6.5Â âÂ 7.5.
</paragraph>
               </text>
               <effectiveTime value="20241220"/>
               <component>
                  <observationMedia ID="mm01">
                     <text>Structural Formula
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-uspi-chem-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s70">
               <id root="128d4c38-e932-41cd-ac87-0acd44ab302e"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY
</title>
               <effectiveTime value="20241220"/>
               <component>
                  <section ID="s71">
                     <id root="bff2c4ff-1f9b-4c55-be8e-9cb448fb13c9"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action
</title>
                     <text>
                        <paragraph>Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It contains a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1.
</paragraph>
                        <paragraph>GLP-1 is a physiological regulator of appetite and caloric intake. Nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake.
</paragraph>
                        <paragraph>Both GIP receptors and GLP-1 receptors are found in areas of the brain involved in appetite regulation. Animal studies show that tirzepatide distributes to and activates neurons in brain regions involved in regulation of appetite and food intake.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s72">
                     <id root="269c0aa5-77b5-4845-b825-a901def1641c"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics
</title>
                     <text>
                        <paragraph>Tirzepatide lowers body weight with greater fat mass loss than lean mass loss.
</paragraph>
                        <paragraph>Tirzepatide decreases calorie intake. The effects are likely mediated by affecting appetite.
</paragraph>
                        <paragraph>Tirzepatide stimulates insulin secretion in a glucose-dependent manner and reduces glucagon secretion. Tirzepatide increases insulin sensitivity, as demonstrated in a hyperinsulinemic euglycemic clamp study in patients with typeÂ 2 diabetes mellitus after 28Â weeks of treatment. These effects can lead to a reduction of blood glucose.
</paragraph>
                        <paragraph>Tirzepatide delays gastric emptying. The delay is largest after the first dose and this effect diminishes over time.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s73">
                     <id root="f23a865d-cdcf-4c8b-903e-adddc83baf67"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics
</title>
                     <text>
                        <paragraph>The pharmacokinetics of tirzepatide is similar between healthy subjects, patients with overweight or obesity, and patients with OSA and obesity. Steady-state plasma tirzepatide concentrations were achieved following 4Â weeks of once weekly administration. Tirzepatide exposure increases in a dose-proportional manner.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                     <component>
                        <section ID="s74">
                           <id root="e044c33a-ef85-4ceb-94e8-b955e47975eb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>Following subcutaneous administration, the median time (range) to maximum plasma concentration of tirzepatide is 24Â hours (8 to 72Â hours). The mean absolute bioavailability of tirzepatide following subcutaneous administration is 80%. Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm.
</paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s75">
                           <id root="55203d0d-272a-4e45-9adb-c39600e0f773"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>The mean [coefficient of variation (CV)%] apparent steady-state volumes of distribution of tirzepatide following subcutaneous administration in patients with overweight or obesity and patients with OSA and obesity are approximately 9.7Â L (29%) and 11.8Â L (37%), respectively. Tirzepatide is highly bound to plasma albumin (99%).
</paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s76">
                           <id root="bd66197a-e535-42e3-805c-39dab1c51c34"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The apparent population mean clearance of tirzepatide in patients with overweight or obesity and patients with OSA and obesity is approximately 0.06Â L/h (CV% ~ 20%). The elimination half-life is approximately 5-6Â days in patients with overweight or obesity, and in patients with OSA and obesity.
</paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                           <component>
                              <section ID="s77">
                                 <id root="d9b2921a-7e16-4595-a2f5-c7fa56e1885f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>Tirzepatide is metabolized by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid, and amide hydrolysis.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241220"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s78">
                                 <id root="32149706-b39f-4dc9-a02f-8d8f5e886f3b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>The primary excretion routes of tirzepatide metabolites are via urine and feces. Intact tirzepatide is not observed in urine or feces.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241220"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s79">
                           <id root="fb645f61-c2ca-4d65-97ae-5e9773eadcfe"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>The intrinsic factors of age (18 to 84Â years), sex, race (71% White, 11% Asian, 9% American Indian or Alaska Native, and 8% Black or African American), ethnicity, or body weight do not have a clinically relevant effect on the PK of tirzepatide.
</paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                           <component>
                              <section ID="s80">
                                 <id root="a7810e3f-aa48-461e-b9e7-6bd5221ba2b8"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>Renal impairment does not impact the pharmacokinetics of tirzepatide. The pharmacokinetics of tirzepatide after a single 5Â mg dose were evaluated in patients with different degrees of renal impairment (mild, moderate, severe, ESRD) compared with subjects with normal renal function. Data from clinical studies have also shown that renal impairment in patients with overweight or obesity does not impact the pharmacokinetics of tirzepatide <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s66">8.6</linkHtml>)]</content>.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241220"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s81">
                                 <id root="81611ccc-975e-40e0-9d2b-d2fa84fcb1e4"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>Hepatic impairment does not impact the pharmacokinetics of tirzepatide. The pharmacokinetics of tirzepatide after a single 5Â mg dose were evaluated in patients with different degrees of hepatic impairment (mild, moderate, severe) compared with subjects with normal hepatic function <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s67">8.7</linkHtml>)]</content>.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241220"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s82">
                           <id root="cd67af4f-6e33-4cbb-a3a1-94d08e48e143"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                           <component>
                              <section ID="s83">
                                 <id root="e205caf2-16b4-4efd-af95-8cfc08ce272b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Potential for Tirzepatide to Influence the Pharmacokinetics of Other Drugs</content>
                                    </paragraph>
                                    <paragraph>In vitro studies have shown low potential for tirzepatide to inhibit or induce CYP enzymes, and to inhibit drug transporters.
</paragraph>
                                    <paragraph>ZEPBOUND delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s51">7.2</linkHtml>)]</content>.
</paragraph>
                                    <paragraph>The impact of tirzepatide on gastric emptying was greatest after a single dose of 5Â mg and diminished after subsequent doses.
</paragraph>
                                    <paragraph>Following a first dose of tirzepatide 5Â mg, acetaminophen maximum concentration (C<sub>max</sub>) was reduced by 55%, and the median peak plasma concentration (t<sub>max</sub>) occurred 1Â hour later. After coadministration at Week 6 with tirzepatide 15Â mg, there was no meaningful impact on acetaminophen C<sub>max</sub> and t<sub>max</sub>. Overall acetaminophen exposure (AUC<sub>0</sub>
                                       <sub>-24hr</sub>) was not influenced.
</paragraph>
                                    <paragraph>Following administration of a combined oral contraceptive (0.035Â mg ethinyl estradiol and 0.25Â mg norgestimate) in the presence of a single dose of tirzepatide 5Â mg, mean C<sub>max</sub> of ethinyl estradiol, norgestimate, and norelgestromin was reduced by 59%, 66%, and 55%, while mean AUC was reduced by 20%, 21%, and 23%, respectively. A delay in t<sub>max</sub> of 2.5 to 4.5Â hours was observed.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241220"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s84">
                     <id root="6fe34da7-828b-4da4-bc35-1a65ca4dada5"/>
                     <code code="88830-5" codeSystem="2.16.840.1.113883.6.1" displayName="IMMUNOGENICITY"/>
                     <title>12.6 Immunogenicity
</title>
                     <text>
                        <paragraph>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies.
</paragraph>
                        <paragraph>The incidence of anti-drug antibodies (ADA) to ZEPBOUND was evaluated in adult patients with overweight or obesity or with OSA and obesity in clinical studies lasting 52Â weeks or longer. Anti-tirzepatide antibodies were detected in 64.5% (1591/2467) of ZEPBOUND-treated patients in weight reduction clinical studies 1 and 2, and 60.6% (137/226) of ZEPBOUND-treated patients in OSA clinical studies <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s87">14</linkHtml>)]</content>.
</paragraph>
                        <paragraph>Of the ZEPBOUND-treated patients in weight reduction clinical studies 40% and 16.5% of patients developed antibodies that were cross-reactive to native GIP or native GLP-1, respectively.
</paragraph>
                        <paragraph>Of the ZEPBOUND-treated patients in OSA clinical studies, 37.2% and 19.5% of patients developed antibodies that were cross reactive to native GIP and native GLP-1, respectively.
</paragraph>
                        <paragraph>Neutralizing antibodies against tirzepatide activity on the GIP or GLP-1 receptors and against native GIP or GLP-1 were detected in 2.8% and 2.7% and 0.8% and 0.1% respectively, of ZEPBOUND-treated patients in weight reduction clinical studies.
</paragraph>
                        <paragraph>No ZEPBOUND-treated patients in OSA studies developed neutralizing antibodies against tirzepatide activity on the GIP or GLP-1 receptors or against native GIP or native GLP-1.
</paragraph>
                        <paragraph>No clinically significant effect of anti-tirzepatide antibodies on pharmacokinetics or effectiveness of ZEPBOUND has been identified. More ZEPBOUND-treated patients who developed anti-tirzepatide antibodies experienced hypersensitivity reactions or injection site reactions than those who did not develop these antibodies <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s28">6.1</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s85">
               <id root="70440f04-aff6-4840-ab18-22b59f721a77"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY
</title>
               <effectiveTime value="20241220"/>
               <component>
                  <section ID="s86">
                     <id root="d35e291d-1281-4b15-b6b3-60b759e8b706"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</title>
                     <text>
                        <paragraph>A 2-year carcinogenicity study was conducted with tirzepatide in male and female rats at doses of 0.15, 0.50, and 1.5Â mg/kg (0.1-, 0.4-, and 1-fold the MRHD of 15Â mg once weekly based on AUC) administered by subcutaneous injection twice weekly. A statistically significant increase in thyroid C-cell adenomas was observed in male rats (â¥0.5Â mg/kg) and female rats (â¥0.15Â mg/kg), and a statistically significant increase in thyroid C-cell adenomas and carcinomas combined was observed in male and female rats at all doses examined. In a 6-month carcinogenicity study in rasH2 transgenic mice, tirzepatide at doses of 1, 3, and 10Â mg/kg administered by subcutaneous injection twice weekly was not tumorigenic.
</paragraph>
                        <paragraph>Tirzepatide was not genotoxic in a rat bone marrow micronucleus assay.
</paragraph>
                        <paragraph>In fertility and early embryonic development studies, male and female rats were administered twice weekly subcutaneous doses of 0.5, 1.5, or 3Â mg/kg (0.3-, 1-, and 2-fold and 0.3-, 0.9-, and 2-fold, respectively, the MRHD of 15Â mg once weekly based on AUC). No effects of tirzepatide were observed on sperm morphology, mating, fertility, and conception. In female rats, an increase in the number of females with prolonged diestrus and a decrease in the mean number of corpora lutea resulting in a decrease in the mean number of implantation sites and viable embryos was observed at all dose levels. These effects were considered secondary to the pharmacological effects of tirzepatide on food consumption and body weight.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s87">
               <id root="ef5a1404-c9e7-4c20-83c2-5103e10fb216"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES
</title>
               <effectiveTime value="20241220"/>
               <component>
                  <section ID="s88">
                     <id root="0b787c02-1c06-4e94-9f21-8cd73bb2b2b0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Weight Reduction and Long-Term Maintenance Studies in Adults with Obesity or Overweight
</title>
                     <effectiveTime value="20241220"/>
                     <component>
                        <section ID="s89">
                           <id root="bc06e9ba-9f3b-42e9-b865-1a3a32631503"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Weight Reduction in Adults with Obesity or Overweight, with or without Type</content>
                                 <content styleCode="underline">Â </content>
                                 <content styleCode="underline">2 Diabetes Mellitus (Study 1 and Study 2)</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                           <component>
                              <section ID="s90">
                                 <id root="fb324ba9-d88d-4fc0-8514-8271b2dec56a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Overview of Study 1 and Study 2</content>
                                    </paragraph>
                                    <paragraph>The efficacy of ZEPBOUND for weight reduction in conjunction with a reduced-calorie diet and increased physical activity was studied in two randomized, double-blind, placebo-controlled fixed-dosage trials (Study 1 and Study 2) in adults aged 18Â years and older. In Studies 1 and 2, all patients received a standard lifestyle intervention which included instruction on a reduced-calorie diet (approximately 500Â kcal/day deficit) and increased physical activity counseling (recommended minimum of 150Â min/week) that began with the first dose of study medication or placebo and continued throughout the trial. Patients also received counseling on behavior modification strategies to adhere to diet and exercise recommendations. In both trials, weight reduction was assessed after 72Â weeks of treatment (at least 52Â weeks at maintenance dose).
</paragraph>
                                    <paragraph>Study 1 (NCT04184622) was a 72-week trial that enrolled 2,539 adult patients with obesity (BMI â¥30Â kg/m<sup>2</sup>), or with overweight (BMI 27 to &lt;30Â kg/m<sup>2</sup>) and at least one weight-related comorbid condition, such as dyslipidemia, hypertension, obstructive sleep apnea, or cardiovascular disease; patients with typeÂ 2 diabetes mellitus were excluded. Patients were randomized in a 1:1:1:1 ratio to once weekly fixed dosage of ZEPBOUND 5Â mg, ZEPBOUND 10Â mg, ZEPBOUND 15Â mg, or placebo, with an escalation period of up to 20Â weeks followed by the maintenance period. At baseline, mean age was 45Â years (range 18-84Â years), 68% were female, 71% were White, 11% were Asian, 9% were American Indian/Alaska Native, and 8% were Black or African American. A total of 48% were Hispanic or Latino ethnicity. Mean baseline body weight was 104.8Â kg and mean BMI was 38Â kg/m<sup>2</sup>. Baseline characteristics included 32% with hypertension, 30% with dyslipidemia, 8% with obstructive sleep apnea, and 3% with cardiovascular disease.
</paragraph>
                                    <paragraph>Study 2 (NCT04657003) was a 72-week trial that enrolled 938 adult patients with BMI â¥27Â kg/m<sup>2</sup> and typeÂ 2 diabetes mellitus. Patients included in the trial had HbA1c 7-10% and were treated with either diet and exercise alone, or any oral anti-hyperglycemic agent except dipeptidyl peptidase-4 (DPP-4) inhibitors or GLP-1 receptor agonists. Patients who were taking insulin or injectable GLP-1 receptor agonists for typeÂ 2 diabetes mellitus were excluded. Patients were randomized in a 1:1:1 ratio to once weekly fixed dosage of ZEPBOUND 10Â mg, ZEPBOUND 15Â mg, or placebo with an escalation period of up to 20Â weeks followed by the maintenance period. At baseline, mean age was 54Â years (range 18-85Â years), 51% were female, 76% were White, 13% were Asian, and 8% were Black or African American. A total of 60% were Hispanic or Latino ethnicity. Mean baseline body weight was 100.7Â kg and mean BMI was 36.1Â kg/m<sup>2</sup>. Baseline characteristics included 66% with hypertension, 61% with dyslipidemia, 8% with obstructive sleep apnea, and 10% with cardiovascular disease.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241220"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s91">
                                 <id root="43004f38-f4eb-4550-a6df-674da01e1070"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Results for Study 1 and Study 2</content>
                                    </paragraph>
                                    <paragraph>The proportions of patients who discontinued study drug in Study 1 were 14.3%, 16.4%, and 15.1% for the 5Â mg, 10Â mg, and 15Â mg ZEPBOUND-treated groups, respectively, and 26.4% for the placebo-treated group. The proportions of patients who discontinued study drug in Study 2 were 9.3% and 13.8% for the 10Â mg and 15Â mg ZEPBOUND-treated groups, respectively, and 14.9% for the placebo-treated group.
</paragraph>
                                    <paragraph>For Studies 1 and 2, weight reduction was assessed after 72Â weeks of treatment (at least 52Â weeks at maintenance dose). In both studies, the primary efficacy parameters were mean percent change in body weight and the percentage of patients achieving â¥5% weight reduction from baseline to Week 72 (see <linkHtml href="#t2">TableÂ 2</linkHtml>).
</paragraph>
                                    <paragraph>After 72Â weeks of treatment, ZEPBOUND resulted in a statistically significant reduction in body weight compared with placebo, and greater proportions of patients treated with ZEPBOUND 5Â mg, 10Â mg, and 15Â mg achieved at least 5% weight reduction compared to placebo. Among patients treated with ZEPBOUND 10Â mg and 15Â mg, greater proportions of patients achieved at least 10%, 15%, and 20% weight reduction compared to placebo (see <linkHtml href="#t2">TableÂ 2</linkHtml>). A reduction in body weight was observed with ZEPBOUND irrespective of age, sex, race, ethnicity, baseline BMI, and glycemic status.
</paragraph>
                                    <table ID="t2" width="100%">
                                       <caption>Table 2: Changes in Body Weight at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight
</caption>
                                       <col width="17.352%" align="left"/>
                                       <col width="8.189%" align="left"/>
                                       <col width="13.089%" align="left"/>
                                       <col width="13.089%" align="left"/>
                                       <col width="13.089%" align="left"/>
                                       <col width="8.189%" align="left"/>
                                       <col width="13.089%" align="left"/>
                                       <col width="13.914%" align="left"/>
                                       <tfoot>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; N = number of patients randomly assigned to study drug.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>a</sup> The intention-to-treat population includes all randomly assigned patients. For Study 1 at Week 72, body weight was missing for 21.6%, 10.2%, 10.5%, and 9.4% of patients randomly assigned to placebo, ZEPBOUND 5Â mg, 10Â mg, and 15Â mg, respectively. For Study 2 at Week 72, body weight was missing for 11.1%, 4.8%, and 8.4% of patients randomly assigned to placebo, ZEPBOUND 10Â mg, and 15Â mg, respectively. The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19).
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>b</sup> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>c</sup> Analyzed using logistic regression adjusted for baseline value.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>d</sup> p-value&lt;0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>e</sup> Not controlled for type I error rate.
</paragraph>
                                             </td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Toprule Lrule Rrule"/>
                                             <td colspan="4" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">Study 1</content>
                                             </td>
                                             <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">Study 2</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <br/>Intention-to-Treat (ITT) Population<sup>a</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">
                                                   <br/>
                                                </content>
                                                <content styleCode="bold">Placebo<br/>N = 643</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">ZEPBOUND<br/>5Â mg<br/>N = 630</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">ZEPBOUND<br/>10Â mg<br/>N = 636</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">ZEPBOUND<br/>15Â mg<br/>N = 630</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">
                                                   <br/>Placebo<br/>N = 315</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">ZEPBOUND<br/>10Â mg<br/>N = 312</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">ZEPBOUND<br/>15Â mg<br/>N = 311</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Body Weight
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline mean (kg)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">104.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">102.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">105.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">105.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">101.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">100.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">99.6
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % Change from baseline<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-3.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-15.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-19.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-20.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-3.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-12.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-14.7
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % Difference from placebo<sup>b</sup>
                                                <br/>Â  Â  Â  (95% CI)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-11.9<br/>(-13.4, <sup>_</sup>10.4)<sup>d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-16.4<br/>(<sup>_</sup>17.9, -14.8)<sup>d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-17.8<br/>(<sup>_</sup>19.3, -16.3)<sup>d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-9.6<br/>(-11.1, -8.1)<sup>d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-11.6<br/>(-13.0, -10.1)<sup>d</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">% of Patients losing â¥5% body weight
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">34.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">85.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">88.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">90.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">32.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">79.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">82.8
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % Difference from placebo<br/>Â  Â  Â  (95% CI)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">50.3<br/>(44.3, 56.2)<sup>c,d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">54.6<br/>(49.1, 60.0)<sup>c,d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">56.4<br/>(50.9, 62.0)<sup>c,d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">46.8<br/>(39.5, 54.1)<sup>c,d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">50.4<br/>(43.1, 57.8)<sup>c,d</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">% of Patients losing â¥10% body weight
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">18.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">68.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">78.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">83.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">9.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">60.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">64.8
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % Difference from placebo<br/>Â  Â  Â  (95% CI)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">49.3<br/>(43.6, 54.9)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">59.5<br/>(54.2, 64.9)<sup>c,d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">64.8<br/>(59.6, 70.1)<sup>c,d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">51.0<br/>(44.4, 57.7)<sup>c,d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">55.3<br/>(48.6, 62.0)<sup>c,d</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">% of Patients losing â¥15% body weight
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">8.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">48.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">66.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">70.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">39.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">48.0
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % Difference from placebo<br/>Â  Â  Â  (95% CI)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">38.7<br/>(33.6, 43.7)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">58.1<br/>(53.2, 63.0)<sup>c,d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">62.0<br/>(57.2, 66.8)<sup>c,d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">37.0<br/>(31.1, 42.9)<sup>c,d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">45.4<br/>(39.4, 51.4)<sup>c,d</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">% of Patients losing â¥20% body weight
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">3.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">30.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">50.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">56.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">1.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">21.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">30.8
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % Difference from placebo<br/>Â  Â  Â  (95% CI)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">26.6<br/>(22.4, 30.7)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">47.3<br/>(42.7, 51.9)<sup>c,d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">53.8<br/>(49.3, 58.3)<sup>c,d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">20.5<br/>(15.7, 25.4)<sup>c,d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">29.7<br/>(24.3, 35.0)<sup>c,d</sup>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>The cumulative frequency distributions of change in body weight are shown in <linkHtml href="#fig1">FigureÂ 1</linkHtml> for Study 1 and <linkHtml href="#fig2">FigureÂ 2</linkHtml> for Study 2. One way to interpret this figure is to select a change in body weight of interest on the horizontal axis and note the corresponding proportions of patients (vertical axis) in each treatment group who achieved at least that degree of weight reduction. For example, note that the vertical line arising from -10% in <linkHtml href="#fig1">FigureÂ 1</linkHtml> intersects the ZEPBOUND 15Â mg and placebo curves at approximately 83.5%, and 18.8%, respectively, which correspond to the values shown in <linkHtml href="#t2">TableÂ 2</linkHtml>.
</paragraph>
                                    <paragraph ID="fig1">
                                       <content styleCode="bold">Figure 1: Changes in Body Weight (%) from Baseline to Week 72 in Study 1 in Patients with Obesity or Overweight (without Type</content>Â <content styleCode="bold">2 Diabetes)</content>
                                    </paragraph>
                                    <renderMultiMedia ID="f02" referencedObject="mm02"/>
                                    <paragraph>Note: Based on average percent weight change of each randomized patient within each specific treatment arm from 100 imputed datasets including observed data and imputed data using hybrid approach for missing values.
</paragraph>
                                    <paragraph ID="fig2">
                                       <content styleCode="bold">Figure 2: Changes in Body Weight (%) from Baseline to Week 72 in Study 2 in Patients with Obesity or Overweight and Type</content>Â <content styleCode="bold">2 Diabetes</content>
                                    </paragraph>
                                    <renderMultiMedia ID="f03" referencedObject="mm03"/>
                                    <paragraph>Note: Based on average percent weight change of each randomized patient within each specific treatment arm from 100 imputed datasets including observed data and imputed data using hybrid approach for missing values.
</paragraph>
                                    <paragraph>The time courses of weight reduction with ZEPBOUND and placebo from baseline through Week 72 are depicted in <linkHtml href="#fig3">FigureÂ 3</linkHtml> for Study 1 and <linkHtml href="#fig4">FigureÂ 4</linkHtml> for Study 2.
</paragraph>
                                    <paragraph ID="fig3">
                                       <content styleCode="bold">Figure 3: Change from Baseline (%) in Body Weight in Study 1 in Patients with Obesity or Overweight (without Type</content>Â <content styleCode="bold">2 Diabetes)</content>
                                    </paragraph>
                                    <renderMultiMedia ID="f04" referencedObject="mm04"/>
                                    <paragraph>Note: Displayed results are from the Intent-to-Treat Population. (1) Observed mean value from Week 0 to Week 72, and (2) least-squares mean Â± standard error at Week 72 hybrid imputation (HI).
</paragraph>
                                    <paragraph ID="fig4">
                                       <content styleCode="bold">Figure 4: Change from Baseline (%) in Body Weight in Study 2 in Patients with Obesity or Overweight and Type</content>Â <content styleCode="bold">2 Diabetes</content>
                                    </paragraph>
                                    <renderMultiMedia ID="f05" referencedObject="mm05"/>
                                    <paragraph>Note: Displayed results are from the Intent-to-Treat Population. (1) Observed mean value from Week 0 to Week 72, and (2) least squares mean Â± standard error at Week 72 hybrid imputation (HI).
</paragraph>
                                    <paragraph>Changes in waist circumference and cardiometabolic parameters with ZEPBOUND are shown in <linkHtml href="#t3">TableÂ 3</linkHtml> for Study 1 and Study 2.
</paragraph>
                                    <table ID="t3" width="100%">
                                       <caption>Table 3: Changes in Anthropometry and Cardiometabolic Parameters at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight
</caption>
                                       <col width="19.802%" align="left"/>
                                       <col width="9.001%" align="left"/>
                                       <col width="12.277%" align="left"/>
                                       <col width="12.277%" align="left"/>
                                       <col width="12.277%" align="left"/>
                                       <col width="9.001%" align="left"/>
                                       <col width="13.089%" align="left"/>
                                       <col width="12.277%" align="left"/>
                                       <tfoot>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; N = number of patients randomly assigned to study drug.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>a</sup> The intention-to-treat population includes all randomly assigned patients. The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19).
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>b</sup> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>c</sup> Analyzed using log-transformed data.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>d</sup> p-value&lt;0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>e</sup> Not controlled for type I error rate.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>f</sup> Least-squares mean from mixed model for repeated measures adjusted for baseline value and other stratification factors.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>g</sup> Baseline value is the geometric mean.
</paragraph>
                                             </td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Toprule Lrule Rrule"/>
                                             <td colspan="4" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">Study 1</content>
                                             </td>
                                             <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">Study 2</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <br/>Intention-to-Treat (ITT) Population<sup>a</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">
                                                   <br/>
                                                </content>
                                                <content styleCode="bold">Placebo<br/>N = 643</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">ZEPBOUND<br/>5Â mg<br/>N = 630</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">ZEPBOUND<br/>10Â mg<br/>N = 636</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">ZEPBOUND<br/>15Â mg<br/>N = 630</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">
                                                   <br/>Placebo<br/>N = 315</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">ZEPBOUND<br/>10Â mg<br/>N = 312</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">ZEPBOUND<br/>15Â mg<br/>N = 311</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Waist Circumference (cm)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline mean
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">114.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">113.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">114.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">114.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">116.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">114.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">114.6
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change from baseline<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-4.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-14.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-17.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-18.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-3.3
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-10.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-13.1
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Difference from <br/>Â  Â  Â placebo<sup>b</sup> (95% CI)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-10.1<br/>(-11.6, -8.6)<sup>e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-13.8<br/>(-15.2, -12.3)<sup>d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-14.5<br/>(-15.9, -13.0)<sup>d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-7.4<br/>(-9.0, -5.9)<sup>d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-9.8<br/>(-11.2, -8.3)<sup>d</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Systolic Blood Pressure (mmHg)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline mean
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">122.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">123.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">123.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">123.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">131.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">130.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">130.0
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change from baseline<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-1.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-6.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-7.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-7.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-1.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-5.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-7.1
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Difference from <br/>Â  Â  Â placebo<sup>b</sup> (95% CI)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-5.6<br/>(-7.2, -3.9)<sup>e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-6.7<br/>(-8.4, -5.0)<sup>e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-6.4<br/>(-8.0, -4.8)<sup>e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-4.4<br/>(-6.7, -2.1)<sup>e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-5.9<br/>(-8.3, -3.6)<sup>e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Diastolic Blood Pressure (mmHg)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline mean
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">79.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">79.3
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">79.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">79.3
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">79.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">80.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">79.7
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change from baseline<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-0.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-4.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-5.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-4.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-0.3
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-2.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-2.9
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Difference from <br/>Â  Â  Â placebo<sup>b</sup> (95% CI)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-4.1<br/>(-5.2, -3.0)<sup>e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-4.2<br/>(-5.3, -3.0)<sup>e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-3.7<br/>(-4.8, -2.7)<sup>e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-1.8<br/>(-3.3, -0.4)<sup>e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-2.7<br/>(-4.2, -1.2)<sup>e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Pulse Rate (beats per minute)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline mean
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">72.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">72.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">71.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">72.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">74.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">75.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">75.6
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change from baseline<sup>f</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.3
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-0.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">1.0
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Difference from <br/>Â  Â  Â placebo<sup>f</sup> (95% CI)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.5<br/>(-0.5, 1.5)<sup>e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.2<br/>(1.2, 3.2)<sup>e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.5<br/>(1.5, 3.4)<sup>e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">1.2<br/>(-0.1, 2.5)<sup>e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">1.5<br/>(0.2, 2.8)<sup>e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Total Cholesterol (mg/dL)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline mean<sup>g</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">187.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">187.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">190.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">187.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">174.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">173.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">167.0
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % change from <br/>Â  Â  Â baseline<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-1.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-3.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-4.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-6.3
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-2.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-1.0
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Relative difference <br/>Â  Â  Â from placebo<sup>b</sup> (95% CI)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-2.1<br/>(-4.5, 0.4)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-2.7<br/>(-5.1, -0.2)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-4.6<br/>(-6.8, -2.2)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-5.5<br/>(-8.7, -2.2)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-3.8<br/>(-7.1, -0.3)<sup>c,e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">LDL Cholesterol (mg/dL)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline mean<sup>g</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">109.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">108.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">112.3
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">109.3
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">92.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">90.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">85.7
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % change from <br/>Â  Â  Â baseline<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-1.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-4.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-5.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-7.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">7.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">1.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">4.1
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Relative difference <br/>Â  Â  Â from placebo<sup>b</sup> (95% CI)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-2.9<br/>(-6.6, 0.9)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-4.0<br/>(-7.5, -0.5)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-5.5<br/>(-8.9, -2.0)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-5.2<br/>(-10.1, 0.1)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-3.0<br/>(-8.4, 2.6)<sup>c,e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">HDL Cholesterol (mg/dL)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline mean<sup>g</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">46.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">47.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">47.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">47.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">42.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">43.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">42.2
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % change from <br/>Â  Â  Â baseline<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-0.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">6.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">9.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">8.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">8.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">9.7
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Relative difference <br/>Â  Â  Â from placebo<sup>b</sup> (95% CI)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">7.7<br/>(4.6, 10.8)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">9.9<br/>(6.7, 13.2)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">8.7<br/>(5.7, 11.8)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">8.0<br/>(4.2, 11.8)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">9.5<br/>(5.6, 13.5)<sup>c,e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Non-HDL Cholesterol (mg/dL)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline mean<sup>g</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">138.3
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">137.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">140.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">137.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">129.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">127.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">121.9
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % change from <br/>Â  Â  Â baseline<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-2.3
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-8.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-9.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-11.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">3.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-6.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-5.2
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Relative difference <br/>Â  Â  Â from placebo<sup>b</sup> (95% CI)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-5.8<br/>(-8.9, -2.6)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-7.2<br/>(-10.3, -4.1)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-9.6<br/>(-12.4, -6.6)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-9.9<br/>(-14.1, -5.6)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-8.5<br/>(-12.9, -4.0)<sup>c,e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Triglycerides (mg/dL)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline mean<sup>g</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">130.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">128.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">125.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">128.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">165.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">158.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">158.5
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % change from <br/>Â  Â  Â baseline<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-5.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-21.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-23.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-29.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-3.3
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-27.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-27.3
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Relative difference <br/>Â  Â  Â from placebo<sup>b</sup> (95% CI)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-16.5<br/>(-21.2, -11.4)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-19.3<br/>(-23.9, -14.4)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-24.9<br/>(-29.1, -20.4)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-24.6<br/>(-30.0, -18.7)<sup>c,e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-24.8<br/>(-30.3, -18.9)<sup>c,e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">HbA1c (%)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline mean
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">5.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">5.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">5.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">5.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">8.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">8.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">8.1
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change from baseline<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-0.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-0.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-0.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-0.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-0.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-2.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-2.1
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Difference from <br/>Â  Â  Â placebo<sup>b</sup> (95% CI)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-0.3<br/>(-0.3, -0.2)<sup>e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-0.4<br/>(-0.4, -0.3)<sup>e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-0.4<br/>(-0.4, -0.3)<sup>e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-1.6<br/>(-1.7, -1.4)<sup>d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-1.6<br/>(-1.8, -1.4)<sup>d</sup>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20241220"/>
                                 <component>
                                    <observationMedia ID="mm02">
                                       <text>Figure 1
</text>
                                       <value xsi:type="ED" mediaType="image/jpeg">
                                          <reference value="zep-uspi-fig1-v1.jpg"/>
                                       </value>
                                    </observationMedia>
                                 </component>
                                 <component>
                                    <observationMedia ID="mm03">
                                       <text>Figure 2
</text>
                                       <value xsi:type="ED" mediaType="image/jpeg">
                                          <reference value="zep-uspi-fig2-v1.jpg"/>
                                       </value>
                                    </observationMedia>
                                 </component>
                                 <component>
                                    <observationMedia ID="mm04">
                                       <text>Figure 3
</text>
                                       <value xsi:type="ED" mediaType="image/jpeg">
                                          <reference value="zep-uspi-fig3-v1.jpg"/>
                                       </value>
                                    </observationMedia>
                                 </component>
                                 <component>
                                    <observationMedia ID="mm05">
                                       <text>Figure 4
</text>
                                       <value xsi:type="ED" mediaType="image/jpeg">
                                          <reference value="zep-uspi-fig4-v1.jpg"/>
                                       </value>
                                    </observationMedia>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s92">
                           <id root="78fdf6ac-f896-40f7-825b-672e929420c9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Weight Reduction Following Intensive Lifestyle Intervention in Adults with Obesity or Overweight (Study 3)</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                           <component>
                              <section ID="s93">
                                 <id root="39394026-8a96-47b2-9176-8f6725d11b00"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Overview of Study 3</content>
                                    </paragraph>
                                    <paragraph>Study 3 (NCT04657016) was an 84-week trial with a 12-week intensive lifestyle intervention lead-in period (Week -12 to Week 0), followed by a 72-week randomized treatment period of ZEPBOUND versus placebo (Week 0 to Week 72) with a standard lifestyle intervention. Only patients who lost â¥5% body weight during the 12-week intensive lifestyle lead-in period entered the 72-week randomized treatment period. The trial initially enrolled 806 adult patients (aged 18Â years and older) with obesity (BMI â¥30Â kg/m<sup>2</sup>), or with overweight (BMI 27 to &lt;30Â kg/m<sup>2</sup>) and at least one weight-related comorbid condition, such as dyslipidemia, hypertension, obstructive sleep apnea, or cardiovascular disease; patients with typeÂ 2 diabetes mellitus were excluded. During the intensive lifestyle intervention lead-in period, lifestyle instruction was delivered 8 times over 12Â weeks by a dietician or dietician-equivalent, with all patients receiving instruction to exercise for at least 150Â minutes per week and to reduce their caloric intake to approximately 1,200Â kcal/day (females) or 1,500Â kcal/day (males). Patients also received counseling on behavior modification strategies to adhere to diet and exercise recommendations. At the end of the 12-week intensive lifestyle intervention lead-in period, 579 patients who achieved â¥5% weight reduction were randomized in a 1:1 ratio to ZEPBOUND or placebo for 72Â weeks. ZEPBOUND dosages were escalated over a period of up to 20Â weeks to a maximum tolerated dosage (MTD) of 10Â mg or 15Â mg subcutaneous once weekly. During the randomized treatment period, patients received a standard lifestyle instruction every 12 weeks on reduced-calorie diet (approximately 500Â kcal/day deficit) and increased physical activity (recommended minimum of 150Â min/week) that began with the first dose of ZEPBOUND or placebo and continued throughout the 72-week treatment period; behavior modification strategies were recommended as needed. Weight reduction was assessed after 72Â weeks of treatment (at least 52Â weeks at maintenance dose).
</paragraph>
                                    <paragraph>For the 579 patients who were randomized, mean body weight at enrollment prior to entering the 12-week lifestyle lead-in period (Week -12) was 109.5Â kg and mean BMI was 38.6Â kg/m<sup>2</sup>. At randomization (Week 0), after the 12-week intensive lifestyle lead-in period, mean body weight was 101.9Â kg and mean BMI was 35.9Â kg/m<sup>2</sup>. The mean age of patients randomized to treatment was 46Â years (range 18-77Â years), 63% were female, 86% were White, 11% were Black or African American, and 1% were Asian. A total of 54% were Hispanic or Latino ethnicity. Baseline characteristics for the 579 randomized patients included 34% with hypertension, 26% with dyslipidemia, 10% with obstructive sleep apnea, and 2% with cardiovascular disease.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241220"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s94">
                                 <id root="766ef2b7-4c41-4c8e-90d2-2e7badc71d07"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Results for Study 3</content>
                                    </paragraph>
                                    <paragraph>At the end of the 12-week intensive lifestyle intervention lead-in, for patients who subsequently entered the randomized treatment period (n=579), the average body weight loss due to lifestyle was 6.9% (Week -12 to Week 0). Eighty-six percent (86%) of ZEPBOUND-treated patients had a maximum tolerated dosage of 15Â mg weekly based on their final dose during the double-blind treatment period. The time course of weight reduction during the lead-in and from Week 0 to Week 72 with ZEPBOUND and placebo are depicted in <linkHtml href="#fig5">FigureÂ 5</linkHtml>.
</paragraph>
                                    <paragraph ID="fig5">
                                       <content styleCode="bold">Figure 5: Change in Body Weight (%) After 12-Week Intensive Lifestyle Intervention Lead-In Followed by Randomized Treatment and a Standard Lifestyle Intervention (Study 3) in Patients with Obesity or Overweight</content>
                                    </paragraph>
                                    <renderMultiMedia ID="f06a" referencedObject="mm06a"/>
                                    <paragraph>Note: Displayed results are from the randomized Population. (1) Observed mean value from Week -12 to Week 72, and (2) least squares mean Â± standard error at Week 72 hybrid imputation (HI). Change from Week -12 is not a primary endpoint in Study 3.
</paragraph>
                                    <paragraph>The proportions of patients who discontinued study drug after randomization were 21.3% for the ZEPBOUND-treated group and 30.5% for the placebo-treated group.
</paragraph>
                                    <paragraph>For Study 3, the primary efficacy parameters were mean percent change in body weight from randomization (Week 0) to Week 72 and the percentage of patients achieving â¥5% weight reduction from randomization (Week 0) to Week 72. Amongst randomized patients who already lost â¥5% body weight during the 12-week intensive lifestyle lead-in period, subsequent treatment with ZEPBOUND resulted in a statistically significant reduction in body weight compared to placebo from randomization (Week 0) to Week 72. A greater proportion of patients treated with ZEPBOUND achieved at least 5%, 10%, 15%, and 20% weight reduction from Week 0 to Week 72 compared to placebo (see <linkHtml href="#t4">TableÂ 4</linkHtml>).
</paragraph>
                                    <table ID="t4" width="100%">
                                       <caption>Table 4: Changes in Body Weight After 12-Week Intensive Lifestyle Intervention Lead-In Followed by Randomized Treatment and a Standard Lifestyle Intervention (Study 3) in Patients with Obesity or Overweight
</caption>
                                       <col width="42.833%" align="left"/>
                                       <col width="26.900%" align="left"/>
                                       <col width="30.267%" align="left"/>
                                       <tfoot>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; MTD = maximum tolerated dose; N = number of patients randomly assigned to study drug.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>a</sup> The intent-to-treat population included only randomized patients with â¥5% weight loss at Week 0 after 12Â weeks of intensive lifestyle intervention. During the 12-week lead-in period, 227 of 806 patients (28.2%) discontinued from the study. Of these 141 (17.5%) discontinued due to not achieving the randomization criteria of â¥5% weight reduction.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>b</sup> The intent-to-treat population includes all randomly assigned patients. For Study 3 at Week 72, body weight was missing for 23.6% and 8.7% of patients randomly assigned to placebo and ZEPBOUND MTD (10 or 15Â mg). The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19).
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>c</sup> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>d</sup> Analyzed using logistic regression adjusted for baseline value.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>e</sup> p-value&lt;0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate.
</paragraph>
                                             </td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                             <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">Study 3
																	<br/>
																N = 579<sup>a</sup>
                                                </content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Body weight
</td>
                                             <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Mean (kg) at Week -12
</td>
                                             <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">109.5
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Intention-to-Treat (ITT) Population<sup>a,b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">
                                                   <br/>
                                                </content>
                                                <content styleCode="bold">Placebo<br/> N = 292</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">ZEPBOUND<br/>MTD (10</content>Â <content styleCode="bold">mg or 15</content>Â <content styleCode="bold">mg)<br/> N = 287</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Body Weight
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Mean (kg) at Week 0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">101.3
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">102.5
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % Change from randomization at Week 72<sup>c</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-18.4
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % Difference from placebo, at Week 72<sup>c</sup>
                                                <br/>Â  Â  Â  (95% CI)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-20.8<br/>(-23.2, -18.5)<sup>e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % of Patients losing â¥5% body weight
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">16.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">87.5
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % Difference from placebo<br/>Â  Â  Â  (95% CI)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">71.1<br/>(63.6, 78.5)<sup>d,e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % of Patients losing â¥10% body weight
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">8.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">76.7
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % Difference from placebo<br/>Â  Â  Â  (95% CI)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">67.9<br/>(60.7, 75.1)<sup>d,e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % of Patients losing â¥15% body weight
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">4.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">65.4
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % Difference from placebo<br/>Â  Â  Â  (95% CI)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">61.3<br/>(54.5, 68.1)<sup>d,e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % of Patients losing â¥20% body weight
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">44.7
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % Difference from placebo<br/>Â  Â  Â  (95% CI)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">42.6<br/>(36.0, 49.1)<sup>d,e</sup>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>Changes in waist circumference and cardiometabolic parameters are shown in <linkHtml href="#t5">TableÂ 5</linkHtml>.
</paragraph>
                                    <table ID="t5" width="100%">
                                       <caption>Table 5: Changes in Anthropometry and Cardiometabolic Parameters After 12-Week Intensive Lifestyle Intervention Lead-In Followed by Randomized Treatment and a Standard Lifestyle Intervention (Study 3) in Patients with Obesity or Overweight
</caption>
                                       <col width="15.425%" align="left"/>
                                       <col width="10.538%" align="left"/>
                                       <col width="11.500%" align="left"/>
                                       <col width="12.337%" align="left"/>
                                       <col width="11.675%" align="left"/>
                                       <col width="12.837%" align="left"/>
                                       <col width="11.675%" align="left"/>
                                       <col width="14.013%" align="left"/>
                                       <tfoot>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; N = number of patients randomly assigned to study drug.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>a</sup> The intent-to-treat population included all randomly assigned patients. The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19).
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>b</sup> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>c</sup> Analyzed using log-transformed data.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>d</sup> p-value&lt;0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>e</sup> Not controlled for type I error rate.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>f</sup> Least-squares mean from mixed model for repeated measures adjusted for baseline value and other stratification factors.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>g</sup> Baseline and randomization values are the geometric mean.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>h</sup> Observed means are shown for change from Week -12 to Week 0. Least-square means are shown for change from Week 0 to Week 72.
</paragraph>
                                             </td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr>
                                             <td rowspan="2" align="left" valign="bottom" styleCode="Toprule Botrule Lrule Rrule">Intention-to-Treat (ITT) Population<sup>a</sup>
                                             </td>
                                             <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">All Randomized Patients</content>
                                                <content styleCode="bold">
                                                   <br/>
                                                </content>
                                                <content styleCode="bold">N=579</content>
                                             </td>
                                             <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">Placebo<br/>N=292</content>
                                             </td>
                                             <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">ZEPBOUND MTD (10</content>Â <content styleCode="bold">mg or 15</content>Â <content styleCode="bold">mg)<br/>N=287</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">Baseline (Week
</content>
                                                <content styleCode="bold">-</content>
                                                <content styleCode="bold">12)</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">Change from Week
</content>
                                                <content styleCode="bold">-</content>
                                                <content styleCode="bold">12 to Week 0</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">Randomization (Week 0)</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">Change from Week 0 to Week 72</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">Randomization (Week 0)</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">Change from Week 0 to Week 72</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">Difference from placebo, Week 0 to Week 72</content>
                                                <content styleCode="bold">
                                                   <br/>
                                                </content>
                                                <content styleCode="bold">(95% CI)</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Waist circumference (cm)<sup>h</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">116.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-6.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">109.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.2<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">109.3
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-14.6<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-14.8<sup>b</sup>
                                                <br/>(-17.2, -12.5)<sup>d</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Systolic Blood Pressure (mmHg)<sup>h</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">126.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-5.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">120.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">3.5<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">121.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-5.1<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-8.6<sup>b</sup>
                                                <br/>(-11.3, -6.0)<sup>e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Diastolic Blood Pressure (mmHg)<sup>h</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">81.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-2.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">78.3
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.1<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">79.3
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-3.2<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-5.3<sup>b</sup>
                                                <br/>(-6.9, -3.7)<sup>e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Pulse Rate (beats per minute)<sup>h</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">73.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-1.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">70.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.9<sup>f</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">72.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.7<sup>f</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">1.8<sup>f</sup>
                                                <br/>(0.3, 3.4)<sup>e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">HbA1c (%)<sup>h</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">5.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-0.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">5.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.0<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">5.3
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-0.4<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-0.4<sup>b</sup>
                                                <br/>(-0.5, -0.3)<sup>e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Total Cholesterol (mg/dL)<sup>g,h</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">190.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-8.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">181.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">4.3
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">181.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-2.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-6.4<sup>b</sup>
                                                <br/>(-9.0, -3.6)<sup>c,e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">LDL Cholesterol (mg/dL)<sup>g,h</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">111.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-3.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">107.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">4.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">108.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-5.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-9.6<sup>b</sup>
                                                <br/>(-13.7, -5.4)<sup>c,e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">HDL Cholesterol (mg/dL)<sup>g,h</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">48.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-1.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">47.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">5.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">46.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">15.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">9.3<sup>b</sup>
                                                <br/>(4.5, 14.2)<sup>c,e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Non-HDL Cholesterol (mg/dL)<sup>g,h</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">139.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-7.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">131.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">4.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">132.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-8.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-12.6<sup>b</sup>
                                                <br/>(-15.9, -9.3)<sup>c,e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Triglycerides (mg/dL)<sup>g,h</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">123.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-19.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">108.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">111.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-23.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-25.1<sup>b</sup>
                                                <br/>(-30.9, -18.9)<sup>c,e</sup>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20241220"/>
                                 <component>
                                    <observationMedia ID="mm06a">
                                       <text>Figure 5
</text>
                                       <value xsi:type="ED" mediaType="image/jpeg">
                                          <reference value="zep-uspi-fig5-v1.jpg"/>
                                       </value>
                                    </observationMedia>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s95">
                           <id root="694d0b4e-e019-4932-8b88-15d6943c792f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Weight Reduction Following Randomized Withdrawal in Adults with Obesity or Overweight (Study 4)</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                           <component>
                              <section ID="s96">
                                 <id root="9079b22f-47cb-42f1-8939-8aa0b0768440"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Overview of Study 4</content>
                                    </paragraph>
                                    <paragraph>Study 4 (NCT04660643) was an 88-week randomized withdrawal trial in which all patients received open-label ZEPBOUND during a 36-week lead-in period, followed by randomization to either continue ZEPBOUND or switch to placebo for 52Â weeks. The trial enrolled 783 adult patients (aged 18Â years and older) with obesity (BMI â¥30Â kg/m<sup>2</sup>), or with overweight (BMI 27 to &lt;30Â kg/m<sup>2</sup>) and at least one weight-related comorbid condition, such as dyslipidemia, hypertension, obstructive sleep apnea, or cardiovascular disease; patients with typeÂ 2 diabetes mellitus were excluded. All patients received a standard lifestyle intervention which included instruction on a reduced-calorie diet (approximately 500Â kcal/day deficit) and increased physical activity counseling (recommended minimum of 150Â min/week) that began with the first dose of ZEPBOUND, during the lead-in period, and continued throughout the trial. During the 36-week open-label ZEPBOUND lead-in period, ZEPBOUND dosages were escalated over a period of up to 20Â weeks to an MTD of 10Â mg or 15Â mg subcutaneous once weekly. After the lead-in period, patients were randomized at Week 36 to continue ZEPBOUND or switch to placebo for 52Â weeks.
</paragraph>
                                    <paragraph>Of the 783 patients who started ZEPBOUND at Week 0, 14.4% discontinued treatment before randomization at Week 36, and adverse events were the most common reason for discontinuation (6.8%). At Week 36, a total of 670 patients were randomized in a 1:1 ratio to ZEPBOUND MTD or placebo for 52Â weeks. For the 670 randomized patients, at study entry (Week 0) mean body weight was 107.3Â kg and mean BMI was 38.4Â kg/m<sup>2</sup>, and at randomization (Week 36, after the open-label ZEPBOUND lead-in period) mean body weight was 85.2Â kg and mean BMI was 30.5Â kg/m<sup>2</sup>. Among the randomized patients, the mean age was 49Â years (range 19-81Â years), 71% were female, 80% were White, 11% were Black or African American, and 7% were Asian. A total of 44% were Hispanic or Latino ethnicity. Baseline characteristics for the 670 randomized patients included 35% with hypertension, 32% with dyslipidemia, 12% with obstructive sleep apnea, and 6% with cardiovascular disease.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241220"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s97">
                                 <id root="e4d0eccc-2be8-4efa-b2a3-0c9718797527"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Results for Study 4</content>
                                    </paragraph>
                                    <paragraph>At the end of the 36-week open-label ZEPBOUND lead-in period, of the 670 randomized patients, 93% were on ZEPBOUND MTD of 15Â mg weekly and 7% were on MTD of 10Â mg weekly. After open-label ZEPBOUND treatment, randomized patients (n=670) had an average body weight loss of 20.9% (Week 0 to Week 36). The time course of weight reduction from Week 0 through Week 88 is depicted in <linkHtml href="#fig6">FigureÂ 6</linkHtml>.
</paragraph>
                                    <paragraph ID="fig6">
                                       <content styleCode="bold">Figure 6: Change in Body Weight (%) After 36-Week Open-Label Treatment Followed by Randomized Withdrawal (Study 4) in Patients with Obesity or Overweight</content>
                                    </paragraph>
                                    <renderMultiMedia ID="f07a" referencedObject="mm07a"/>
                                    <paragraph>Note: Displayed results are from the randomized population. (1) Displayed results are observed mean value from Week 0 to Week 88 and (2) least squares mean Â± standard error at Week 88 hybrid imputation (HI). Change from Week 0 was not a primary endpoint in Study 4.
</paragraph>
                                    <paragraph>The proportions of patients who discontinued study drug after randomization at Week 36 were 10.4% for the ZEPBOUND-treated group and 17.9% for the placebo-treated group.
</paragraph>
                                    <paragraph>For Study 4, the primary efficacy parameter was mean percent change in body weight from randomization (Week 36) to Week 88. After weight loss with ZEPBOUND treatment during the open-label lead-in period (Week 0 to Week 36), continued treatment with ZEPBOUND from randomization (Week 36) to Week 88 resulted in a statistically significant reduction in body weight compared with placebo (see <linkHtml href="#t6">TableÂ 6</linkHtml>).
</paragraph>
                                    <table ID="t6" width="100%">
                                       <caption>Table 6: Changes in Body Weight After 36-Week Open-Label Treatment Followed by Randomized Withdrawal (Study 4) in Patients with Obesity or Overweight
</caption>
                                       <col width="38.780%" align="left"/>
                                       <col width="30.610%" align="left"/>
                                       <col width="30.610%" align="left"/>
                                       <tfoot>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; MTD = maximum tolerated dose; N = number of patients randomly assigned to study drug.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>a</sup> The intent-to-treat population included all randomly assigned patients and did not include 113 patients who were enrolled but not randomized. At Week 88, body weight was missing for 13.7% and 7.5% of patients randomly assigned to placebo and ZEPBOUND MTD (10 or 15Â mg), respectively. The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19).
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>b</sup> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>c</sup> Analyzed using logistic regression adjusted for baseline value.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>d</sup> p-value&lt;0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate.
</paragraph>
                                             </td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                             <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">Study 4<br/>N=670</content>
                                                <content styleCode="bold">
                                                   <sup>a</sup>
                                                </content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Body weight
</td>
                                             <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Mean at Week 0 (kg)
</td>
                                             <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">107.3
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Intention-to-Treat (ITT) Population<sup>a</sup>
                                             </td>
                                             <td align="center" valign="bottom" styleCode="Botrule Rrule">
                                                <content styleCode="bold">Placebo<br/>N=335</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">ZEPBOUND<br/>(MTD 10</content>Â <content styleCode="bold">mg or 15</content>Â <content styleCode="bold">mg)<br/>N=335</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Body Weight
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Mean at Week 36 (kg)
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">85.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">84.6
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % change from Week 36 at Week 88<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">14.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-5.5
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % difference from placebo at Week 88<br/>Â  Â  Â  (95% CI)<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-19.4<br/>(-21.2, -17.7)<sup>d</sup>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>Changes in waist circumference and cardiometabolic parameters in Study 4 are shown in <linkHtml href="#t7">TableÂ 7</linkHtml>.
</paragraph>
                                    <table ID="t7" width="100%">
                                       <caption>Table 7: Mean Changes in Anthropometry and Cardiometabolic Parameters After 36-Week Open-Label Treatment Followed by Randomized Withdrawal (StudyÂ 4) in Patients with Obesity or Overweight
</caption>
                                       <col width="15.888%" align="left"/>
                                       <col width="10.425%" align="left"/>
                                       <col width="10.013%" align="left"/>
                                       <col width="13.188%" align="left"/>
                                       <col width="12.488%" align="left"/>
                                       <col width="12.188%" align="left"/>
                                       <col width="11.925%" align="left"/>
                                       <col width="13.888%" align="left"/>
                                       <tfoot>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; N = number of patients randomly assigned to study drug.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>a</sup> The intent-to-treat population included all randomly assigned patients. The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19).
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>b</sup> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>c</sup> Analyzed using log-transformed data.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>d</sup> p-value&lt;0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>e</sup> Not controlled for type I error rate.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>f</sup> Least-squares mean from mixed model for repeated measures adjusted for baseline value and other stratification factors.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>g</sup> Baseline and randomization values are the geometric mean.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="8" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>h</sup> Observed means are shown for change from Week 0 to Week 36. Least-square means are shown for change from Week 36 to Week 88.
</paragraph>
                                             </td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr>
                                             <td rowspan="2" align="left" valign="bottom" styleCode="Toprule Botrule Lrule Rrule">Intention-to-Treat (ITT) Population<sup>a</sup>
                                             </td>
                                             <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">All Randomized Patients</content>
                                                <content styleCode="bold">
                                                   <br/>
                                                </content>
                                                <content styleCode="bold">N=670</content>
                                             </td>
                                             <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">Placebo</content>
                                                <content styleCode="bold">
                                                   <br/>
                                                </content>
                                                <content styleCode="bold">N=335</content>
                                             </td>
                                             <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">ZEPBOUND MTD (10</content>Â <content styleCode="bold">mg or 15</content>Â <content styleCode="bold">mg)</content>
                                                <content styleCode="bold">
                                                   <br/>
                                                </content>
                                                <content styleCode="bold">N=335</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">Baseline (Week 0)</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">Change from Week 0 to Week 36</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">Randomization (Week 36)</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">Change from Week 36 to Week 88</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">Randomization (Week 36)</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">Change from Week 36 to Week 88</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">Difference from placebo, Week 36 to Week 88</content>
                                                <content styleCode="bold">
                                                   <br/>
                                                </content>
                                                <content styleCode="bold">(95% CI)</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Waist circumference (cm)<sup>h</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">115.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-17.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">98.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">7.8<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">96.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-4.3<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-12.1<sup>b</sup>
                                                <br/>(-13.5, -10.6)<sup>d</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Systolic Blood Pressure (mmHg)<sup>h</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">126.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-11.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">114.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">8.2<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">115.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.0<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-6.2<sup>b</sup>
                                                <br/>(-8.2, -4.3)<sup>e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Diastolic Blood Pressure (mmHg)<sup>h</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">80.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-5.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">76.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">3.2<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">75.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-0.7<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-3.8<sup>b</sup>
                                                <br/>(-5.2, -2.4)<sup>e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Pulse Rate (beats per minute)<sup>h</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">72.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">5.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">77.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-5.2<sup>f</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">77.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-2.1<sup>f</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">3.1<sup>f</sup>
                                                <br/>(1.9, 4.3)<sup>e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">HbA1c (%)<sup>h</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">5.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-0.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">5.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.3<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">5.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-0.0<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-0.3<sup>b</sup>
                                                <br/>(-0.3, -0.2)<sup>e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Total Cholesterol (mg/dL)<sup>g,h</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">188.3
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-12.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">176.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">8.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">175.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-4.9<sup>b</sup>
                                                <br/>(-7.4, -2.4)<sup>c,e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">LDL Cholesterol (mg/dL)<sup>g,h</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">108.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-1.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">107.6
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">3.2
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">105.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-3.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-6.5<sup>b</sup>
                                                <br/>(-10.0, -2.9)<sup>c,e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">HDL Cholesterol (mg/dL)<sup>g,h</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">49.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-2.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">47.3
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">14.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">47.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">18.7
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">3.4<sup>b</sup>
                                                <br/>(0.2, 6.6)<sup>c,e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Non-HDL Cholesterol (mg/dL)<sup>g,h</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">135.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-9.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">126.3
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">5.1
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">126.0
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-3.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-8.1<sup>b</sup>
                                                <br/>(-11.3, -4.8)<sup>c,e</sup>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Triglycerides (mg/dL)<sup>g,h</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">121.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-40.4
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">85.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">13.5
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">90.9
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-4.8
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-16.1<sup>b</sup>
                                                <br/>(-21.7, -10.0)<sup>c,e</sup>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20241220"/>
                                 <component>
                                    <observationMedia ID="mm07a">
                                       <text>Figure 6
</text>
                                       <value xsi:type="ED" mediaType="image/jpeg">
                                          <reference value="zep-uspi-fig6-v1.jpg"/>
                                       </value>
                                    </observationMedia>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s98">
                     <id root="b83b2412-4e9b-4880-8532-81472708f386"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Obstructive Sleep Apnea Studies in Adults with Obesity
</title>
                     <effectiveTime value="20241220"/>
                     <component>
                        <section ID="s99">
                           <id root="198b3e2f-8fdd-44b0-8b19-651ef23e4197"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Overview of Study
</content>
                                 <content styleCode="italics">5
</content>
                                 <content styleCode="italics">and Study
</content>
                                 <content styleCode="italics">6</content>
                              </paragraph>
                              <paragraph>The efficacy of ZEPBOUND for moderate to severe obstructive sleep apnea (OSA) (apnea-hypopnea index [AHI] â¥15) in patients with obesity (BMI â¥30Â kg/m<sup>2</sup>) was evaluated in a master protocol clinical trial (NCT05412004) that included two randomized, double-blind, placebo-controlled trials (Study 5 and Study 6) of 52Â weeks duration. The two trials enrolled a total of 469 adult patients.
</paragraph>
                              <paragraph>In Studies 5 and 6, patients were randomized in a 1:1 ratio to receive ZEPBOUND or placebo for 52Â weeks. ZEPBOUND dosages were escalated over a period of up to 20Â weeks to maximum tolerated dosage (MTD) of 10Â mg or 15Â mg subcutaneous once weekly <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s6">2.1</linkHtml>, <linkHtml href="#s7">2.2</linkHtml>)]</content>. Patients with typeÂ 2 diabetes mellitus were excluded and all patients received instruction on a reduced-calorie diet and increased physical activity counseling throughout the study.
</paragraph>
                              <paragraph>Study 5 enrolled 234 adult patients with moderate to severe OSA and obesity who were unable or unwilling to use Positive Airway Pressure (PAP) therapy. Patients had a mean age of 48Â years (range: 20 to 76Â years), 67% were male, 66% were White, 20% were Asian, 8% were American Indian/Alaska Native, and 6% were Black or African American. A total of 42% were Hispanic or Latino ethnicity.
</paragraph>
                              <paragraph>Study 6 enrolled 235 adult patients with moderate to severe OSA and obesity who were on PAP therapy. Patients had a mean age of 52Â years (range: 26 to 79Â years), 72% were male, 73% were White, 14% were Asian, 8% were American Indian/Alaska Native, and 5% were Black or African American. A total of 32% were Hispanic or Latino ethnicity.
</paragraph>
                              <paragraph>
                                 <linkHtml href="#t8">Table 8</linkHtml> describes the baseline disease characteristics of patients in Studies 5 and 6.
</paragraph>
                              <table ID="t8" width="100%">
                                 <caption>Table 8: Baseline Disease Characteristics of Patients with OSA and Obesity in Study 5 and Study 6
</caption>
                                 <col width="41.667%" align="left"/>
                                 <col width="30.867%" align="left"/>
                                 <col width="27.467%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">Abbreviations: AHI = Apnea-Hypopnea Index; BMI = body-mass index; ESS = Epworth Sleepiness Score; OSA = obstructive sleep apnea; SD = standard deviation.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> Moderate OSA was defined as an AHI â¥15 â 30 events/hour on polysomnogram at baseline.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> Severe OSA was defined as an AHI â¥30 events/hour on polysomnogram at baseline.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Study 5 (N=234)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Study 6 (N=235)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Baseline AHI (events/hour), mean (SD)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">51.5 (31)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">49.5 (26.7)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Moderate OSA, %<sup>a</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">35.2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">30.9
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Severe OSA, %<sup>b</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">63.1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">68.2
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">ESS Total, mean (SD)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">10.5 (5.2)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">10 (4.6)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Total Hypoxic Burden (% min/hour), mean (SD)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">208.4 (189.1)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">193 (174.6)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">BMI (kg/m<sup>2</sup>), mean (SD)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">39.1 (7)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">38.7 (6)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Pre-diabetes, %
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">65
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">56.6
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Hypertension, %
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">75.6
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">77.4
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Cardiac disorders, %
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">10.3
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">11.1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Dyslipidemia, %
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">80.8
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">83.8
</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20241220"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s100">
                           <id root="ae0302ba-c429-4f67-a040-81b194ee17d8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Results for Study 5 and Study 6</content>
                              </paragraph>
                              <paragraph>The primary endpoint for Studies 5 and 6 was the change from baseline in the apnea-hypopnea index (AHI) at Week 52. Patients in Study 5 were unable or unwilling to use PAP therapy, and patients in Study 6 were on PAP therapy and instructed to suspend PAP for 7Â days prior to assessment of the primary endpoint. The clinical studies for OSA did not evaluate the timing or appropriateness of PAP discontinuation in patients who were previously compliant with PAP therapy.
</paragraph>
                              <paragraph>In Studies 5 and 6, treatment with ZEPBOUND for 52Â weeks resulted in a statistically significant reduction in AHI compared with placebo, and greater proportions of patients treated with ZEPBOUND achieved remission or mild non-symptomatic OSA compared to placebo. <linkHtml href="#t9">TableÂ 9</linkHtml> provides the efficacy results for Studies 5 and 6. A reduction in AHI was observed with ZEPBOUND irrespective of age, sex, ethnicity, baseline BMI, or baseline OSA severity. In both Studies 5 and 6, patients treated with ZEPBOUND achieved a greater reduction in systolic blood pressure and high-sensitivity C-reactive protein levels compared to placebo.
</paragraph>
                              <table ID="t9" width="100%">
                                 <caption>Table 9: Changes in Apnea-Hypopnea Index (AHI), Hypoxic Burden, and Body Weight at Week 52 in Study 5 and Study 6
</caption>
                                 <col width="41.300%" align="left"/>
                                 <col width="14.060%" align="left"/>
                                 <col width="14.880%" align="left"/>
                                 <col width="14.880%" align="left"/>
                                 <col width="14.880%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">Abbreviations: AHI = Apnea-Hypopnea Index; ANCOVA = analysis of covariance; CI = confidence interval; ESS = Epworth Sleepiness Scale; h = hour; MTD = maximum tolerated dose; N = number of participants randomly assigned and received at least 1 dose of study drug.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> Analyses were based on the modified intent-to-treat population which was defined as randomly assigned participants who were exposed to at least 1 dose of study intervention; two participants in Study 6 were randomized but did not receive study drug.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> Least-squares mean from ANCOVA adjusted for baseline values and stratification factors, with multiple imputation for missing data at WeekÂ 52.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>c</sup> Analyzed using log transformed data.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>d</sup> Calculated by combining proportion of participants achieving target in imputed datasets.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>e</sup> p-value &lt;0.001 (unadjusted 2-sided) for superiority, controlled for multiplicity.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>f</sup> Baseline value is the geometric mean.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td rowspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">Modified Intent-to-Treat (mITT) Population<sup>a</sup>
                                       </td>
                                       <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Study 5</content>
                                       </td>
                                       <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Study 6</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Placebo<br/>N = 120</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">ZEPBOUND MTD (10Â mg or 15Â mg)<br/>N = 114</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">Placebo<br/>N = 114</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <content styleCode="bold">ZEPBOUND MTD (10Â mg or 15Â mg)<br/>N = 119</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">AHI (events/hr)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline mean
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">50.1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">52.9
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">53.1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">46.1
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change from baseline<sup>b</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-5.3
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-25.3
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-5.5
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-29.3
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Difference from placebo<sup>b</sup> (95% CI)
</td>
                                       <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">-20 (-25.8, -14.2)<sup>e</sup>
                                       </td>
                                       <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">-23.8 (-29.6, -17.9)<sup>e</sup>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">% change in AHI
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % change from baseline<sup>b</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-3
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-50.7
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-2.5
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-58.7
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % difference from placebo<sup>b</sup> (95% CI)
</td>
                                       <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">-47.7 (-65.8, -29.6)<sup>e</sup>
                                       </td>
                                       <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">-56.2 (-73.7, -38.7)<sup>e</sup>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">% of patients with â¥50% reduction in AHI<sup>d</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">19
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">61.2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">23.3
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">72.4
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % difference from placebo (95% CI)
</td>
                                       <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">42.8 (30.8, 54.8)<sup>e</sup>
                                       </td>
                                       <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">48.6 (36.6, 60.7)<sup>e</sup>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">Remission or mild non-symptomatic OSA
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % of Patients with AHI &lt;5 or AHI 5-14 and ESSâ¤10<sup>d</sup>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">15.9
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">42.2
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">14.3
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">50.2
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % difference from placebo (95% CI)
</td>
                                       <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">28.7 (18.3, 39.2)<sup>e</sup>
                                       </td>
                                       <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">33.2 (22.1, 44.3)<sup>e</sup>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">Sleep apnea-specific hypoxic burden (% min/h)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline mean<sup>f</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">137.8
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">153.6
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">142.1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">132.2
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Change from baseline<sup>b</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-25.1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-95.2
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-41.7
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-103
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Difference from placebo<sup>b</sup> (95% CI)
</td>
                                       <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">-70.1 (-90.9, -49.3)<sup>c,e</sup>
                                       </td>
                                       <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">-61.3 (-84.7, -37.9)<sup>c,e</sup>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">Body weight (kg)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Baseline mean
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">112.8
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">116.7
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">115.1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">115.8
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % change from baseline<sup>b</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-1.6
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-17.7
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-2.3
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">-19.6
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â % difference from placebo<sup>b</sup> (95% CI)
</td>
                                       <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">-16.1 (-18, -14.2)<sup>e</sup>
                                       </td>
                                       <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">-17.3 (-19.3, -15.3)<sup>e</sup>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>The time course of change in AHI with ZEPBOUND and placebo from baseline through Week 52 are shown in <linkHtml href="#fig7">FigureÂ 7</linkHtml> for StudyÂ 5. Similar results were demonstrated for StudyÂ 6.
</paragraph>
                              <paragraph ID="fig7">
                                 <content styleCode="bold">Figure 7: Change from Baseline in Apnea-Hypopnea Index (AHI) Through Week 52 (Study 5)</content>
                              </paragraph>
                              <renderMultiMedia ID="f08a" referencedObject="mm08a"/>
                              <paragraph>Abbreviations: AHI = Apnea-Hypopnea Index; ANCOVA = analysis of covariance; MI = multiple imputation; MTD = maximum tolerated dose.
</paragraph>
                              <paragraph>Note: Displayed results are from modified Intent-to-Treat Population. (1) Observed mean value from Week 0 through Week 52, and (2) least squares mean Â± standard error at Week 52 from ANCOVA adjusted for baseline values and stratification factors, with multiple imputation of missing data.
</paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                           <component>
                              <observationMedia ID="mm08a">
                                 <text>Figure 7
</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="zep-uspi-fig7-v1.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s101">
                           <id root="57864749-d047-4621-8130-3ccb898036a6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Sleep-Related Impairment</content>
                              </paragraph>
                              <paragraph>In OSA clinical studies (Study 5 and Study 6), ZEPBOUND-treated patients showed improvement in sleep-related impairment compared to those who received placebo. Sleep-related impairment was assessed using the Patient-Reported Outcomes Measurement Information System<sup>Â®</sup> (PROMIS) Short Form Sleep-Related Impairment 8a.
</paragraph>
                           </text>
                           <effectiveTime value="20241220"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s102">
               <id root="62167cca-76a8-4381-bd68-a4e33755e485"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING
</title>
               <effectiveTime value="20241220"/>
               <component>
                  <section ID="s103">
                     <id root="007edd5c-cd7c-496d-a369-9430e1d61467"/>
                     <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
                     <title>16.1 How Supplied
</title>
                     <text>
                        <paragraph>ZEPBOUND (tirzepatide) is a clear, colorless to slightly yellow solution available in cartons containing 4Â pre-filled single-dose pens, 1Â single-dose vial, or 4Â single-dose vials as follows:
</paragraph>
                        <table width="100%">
                           <col width="22.469%" align="left"/>
                           <col width="25.844%" align="left"/>
                           <col width="25.844%" align="left"/>
                           <col width="25.844%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Total Strength per Total Volume</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">4 pack</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">Pen NDC</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">1 pack</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">Vial NDC</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">4 pack<br/>Vial NDC</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">2.5Â mg/0.5Â mL
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">0002-2506-80
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">0002-0152-01
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">0002-0152-04
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">5Â mg/0.5Â mL
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">0002-2495-80
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">0002-0243-01
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">0002-0243-04
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">7.5Â mg/0.5Â mL
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">0002-2484-80
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">0002-1214-01
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">0002-1214-04
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">10Â mg/0.5Â mL
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">0002-2471-80
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">0002-1340-01
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">0002-1340-04
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">12.5Â mg/0.5Â mL
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">0002-2460-80
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">0002-1423-01
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">0002-1423-04
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">15Â mg/0.5Â mL
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">0002-2457-80
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">0002-2002-01
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">0002-2002-04
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s104">
                     <id root="26b7938f-1000-4eb0-927c-cb18e19147af"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.2 Storage and Handling
</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Store ZEPBOUND in a refrigerator at 2Â°C to 8Â°C (36Â°F to 46Â°F).
</item>
                           <item>If needed, each single-dose pen or single-dose vial can be stored unrefrigerated at temperatures not to exceed 30Â°C (86Â°F) for up to 21Â days. If ZEPBOUND is stored at room temperature, it should not be returned to the refrigerator.
</item>
                           <item>Discard if not used within 21Â days after removing from the refrigerator.
</item>
                           <item>Do not freeze ZEPBOUND. Do not use ZEPBOUND if frozen.
</item>
                           <item>Store ZEPBOUND in the original carton to protect from light.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s105">
               <id root="75e0cde2-318b-45a6-baca-9ca18fdf421f"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION
</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling <content styleCode="italics">(Medication Guide and Instructions for Use)</content>.
</paragraph>
               </text>
               <effectiveTime value="20241220"/>
               <component>
                  <section ID="s106">
                     <id root="f22745e6-48fa-409c-841c-1fa6c4c4bca2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk of Thyroid C-Cell Tumors</content>
                        </paragraph>
                        <paragraph>Inform patients that ZEPBOUND causes thyroid C-cell tumors in rats and that the human relevance of this finding has not been determined. Counsel patients to report symptoms of thyroid tumors (e.g., a lump in the neck, persistent hoarseness, dysphagia, or dyspnea) to their healthcare provider <content styleCode="italics">[see <linkHtml href="#s2">Boxed Warning</linkHtml> and Warnings and Precautions (<linkHtml href="#s17">5.1</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s107">
                     <id root="def47df1-363d-4895-83b9-c8d0f68b35ac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Severe Gastrointestinal Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Inform patients of the potential risk of severe gastrointestinal adverse reactions. Instruct patients to contact their healthcare provider if they have severe or persistent gastrointestinal symptoms <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s18">5.2</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s108">
                     <id root="7e478782-2d9e-479d-8abb-e9798deea37e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Acute Kidney Injury</content>
                        </paragraph>
                        <paragraph>Advise patients treated with ZEPBOUND of the potential risk of dehydration due to gastrointestinal adverse reactions and take precautions to avoid fluid depletion. Inform patients of the potential risk for worsening renal function and explain the associated signs and symptoms of renal impairment, as well as the possibility of dialysis as a medical intervention if renal failure occurs <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s19">5.3</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s109">
                     <id root="bfec4990-c42a-4b7f-87cc-7ff4585f7ef0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Acute Gallbladder Disease</content>
                        </paragraph>
                        <paragraph>Inform patients of the risk of acute gallbladder disease. Instruct patients to contact their healthcare provider for appropriate clinical follow-up if gallbladder disease is suspected <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s20">5.4</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s110">
                     <id root="9c9f1139-b44d-4958-8145-4e4ac118f431"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Acute Pancreatitis</content>
                        </paragraph>
                        <paragraph>Inform patients of the potential risk for pancreatitis. Instruct patients to discontinue ZEPBOUND promptly and contact their healthcare provider if pancreatitis is suspected (severe abdominal pain that may radiate to the back, and which may or may not be accompanied by vomiting) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s21">5.5</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s111">
                     <id root="81c05f65-f9ce-4ddc-b6cf-11e4349ff9e5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypersensitivity Reactions</content>
                        </paragraph>
                        <paragraph>Inform patients that serious hypersensitivity reactions have been reported with use of tirzepatide. Advise patients on the symptoms of hypersensitivity reactions and instruct them to stop taking ZEPBOUND and seek medical advice promptly if such symptoms occur <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s22">5.6</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s112">
                     <id root="38dd5f4d-a00d-4230-a5dc-4db6ac58e495"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypoglycemia</content>
                        </paragraph>
                        <paragraph>Inform patients of the risk of hypoglycemia and educate patients on the signs and symptoms of hypoglycemia. Advise patients on insulin or insulin secretagogue therapy that they may have an increased risk of hypoglycemia when using ZEPBOUND and to report signs and/or symptoms of hypoglycemia to their healthcare provider <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s23">5.7</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s113">
                     <id root="a943abee-1531-4396-9693-2adae648ceac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Diabetic Retinopathy Complications</content>
                        </paragraph>
                        <paragraph>Inform patients with typeÂ 2 diabetes mellitus to contact their healthcare provider if changes in vision are experienced during treatment with ZEPBOUND <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s24">5.8</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s114">
                     <id root="443f6d86-e80e-4696-8c8c-bc83679d8d50"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Suicidal Behavior and Ideation</content>
                        </paragraph>
                        <paragraph>Advise patients to report emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Inform patients that if they experience suicidal thoughts or behaviors, they should stop taking ZEPBOUND <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s25">5.9</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s115">
                     <id root="924bfdd5-8c87-40ac-9f9c-b279ab423f9b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pulmonary Aspiration During General Anesthesia or Deep Sedation</content>
                        </paragraph>
                        <paragraph>Inform patients that ZEPBOUND may cause their stomach to empty more slowly which may lead to complications with anesthesia or deep sedation during planned surgeries or procedures. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking ZEPBOUND <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s26">5.10</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s116">
                     <id root="29f51ce4-46b3-4e7a-bfca-afd2ec579fff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy</content>
                        </paragraph>
                        <paragraph>Advise a pregnant patient of the potential risk to a fetus. Advise patients to inform their healthcare provider if they are pregnant or intend to become pregnant during treatment with ZEPBOUND. Advise patients that there will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ZEPBOUND during pregnancy <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s53">8.1</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s117">
                     <id root="1fa3f981-a030-4f44-acb7-d31b209b099a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Contraception</content>
                        </paragraph>
                        <paragraph>Use of ZEPBOUND may reduce the efficacy of oral hormonal contraceptives. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4Â weeks after initiation with ZEPBOUND and for 4Â weeks after each dose escalation <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s51">7.2</linkHtml>), Use in Specific Populations (<linkHtml href="#s62">8.3</linkHtml>), and Clinical Pharmacology (<linkHtml href="#s73">12.3</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s118">
                     <id root="dabb6f9f-1328-4095-ba29-e1806368b343"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Administration</content>
                        </paragraph>
                        <paragraph>Instruct patients how to prepare and administer the correct dose of ZEPBOUND and assess their ability to inject subcutaneously to ensure the proper administration of ZEPBOUND. Instruct patients using the single-dose vial to use a syringe appropriate for dose administration (e.g., a 1Â mL syringe capable of measuring a 0.5Â mL dose) <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s13">2.4</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="s119">
                     <id root="a321edc7-21b6-4f82-b4bb-4f64d8cd298e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Missed Doses</content>
                        </paragraph>
                        <paragraph>Inform patients if a dose is missed, it should be administered as soon as possible within 4Â days after the missed dose. If more than 4Â days have passed, the missed dose should be skipped and the next dose should be administered on the regularly scheduled day. In each case, inform patients to resume their regular once weekly dosing schedule <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s12">2.3</linkHtml>)]</content>.
</paragraph>
                        <paragraph>
                           <content styleCode="bold">Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA</content>
                        </paragraph>
                        <paragraph>Copyright Â© 2023, 2024, Eli Lilly and Company. All rights reserved.
</paragraph>
                        <paragraph>ZEP-0008-USPI-20241220
</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s120">
               <id root="1b9b16a8-c748-4adc-9ab8-2c5e3471387b"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="33.333%" align="left"/>
                     <col width="33.333%" align="left"/>
                     <col width="33.333%" align="left"/>
                     <tfoot>
                        <tr>
                           <td colspan="2" align="left" valign="top">
                              <paragraph styleCode="footnote">This Medication Guide has been approved by the U.S. Food and Drug Administration. 
</paragraph>
                           </td>
                           <td align="right" valign="top">
                              <paragraph styleCode="footnote">Revised: 12/2024
</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Medication Guide</content>
                              <br/>
                              <content styleCode="bold">ZEPBOUND</content>
                              <content styleCode="bold">
                                 <sup>Â®
</sup>
                              </content>
                              <content styleCode="bold">(ZEHP-bownd)</content>
                              <br/>
                              <content styleCode="bold">(tirzepatide)</content>
                              <br/>
                              <content styleCode="bold">injection, for subcutaneous use</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <paragraph ID="p01">
                                 <content styleCode="bold">What is the most important information I should know about ZEPBOUND?</content>
                                 <br/>
                                 <content styleCode="bold">ZEPBOUND may cause serious side effects, including:</content>
                                 <br/>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Possible thyroid tumors, including cancer.</content> Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rats, ZEPBOUND and medicines that work like ZEPBOUND caused thyroid tumors, including thyroid cancer. It is not known if ZEPBOUND will cause thyroid tumors, or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people.
</item>
                                 <item>Do not use ZEPBOUND if you or any of your family have ever had a type of thyroid cancer called MTC, or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome typeÂ 2 (MENÂ 2).
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">What is ZEPBOUND?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>ZEPBOUND is an injectable prescription medicine that may help adults with:<list listType="unordered" styleCode="Disc">
                                       <item>obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.
</item>
                                       <item>moderate to severe obstructive sleep apnea (OSA) and obesity to improve their OSA.
</item>
                                    </list>
                                 </item>
                                 <item>ZEPBOUND should be used with a reduced-calorie diet and increased physical activity.
</item>
                                 <item>ZEPBOUND contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines.
</item>
                                 <item>It is not known if ZEPBOUND is safe and effective for use in children.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Do not use ZEPBOUND if:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>you or any of your family have ever had a type of thyroid cancer called MTC or if you have an endocrine system condition called MENÂ 2.
</item>
                                 <item>you have had a serious allergic reaction to tirzepatide or any of the ingredients in ZEPBOUND. See the end of this Medication Guide for a complete list of ingredients in ZEPBOUND.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">Before using ZEPBOUND, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have or have had problems with your pancreas or kidneys.
</item>
                                 <item>have severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems with digesting food.
</item>
                                 <item>have a history of diabetic retinopathy.
</item>
                                 <item>are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation).
</item>
                                 <item>are pregnant or plan to become pregnant. ZEPBOUND may harm your unborn baby. Tell your healthcare provider if you become pregnant while using ZEPBOUND.<list listType="unordered" styleCode="Circle">
                                       <item>
                                          <content styleCode="bold">Pregnancy Exposure Registry:</content> There will be a pregnancy exposure registry for women who have taken ZEPBOUND during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).
</item>
                                       <item>
                                          <content styleCode="bold">Birth control pills by mouth may not work as well while using ZEPBOUND.</content> If you take birth control pills by mouth, your healthcare provider may recommend another type of birth control for 4Â weeks after you start ZEPBOUND and for 4Â weeks after each increase in your dose of ZEPBOUND. Talk to your healthcare provider about birth control methods that may be right for you while using ZEPBOUND.
</item>
                                    </list>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if ZEPBOUND passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while using ZEPBOUND.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take</content>
                              <content styleCode="bold">,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. ZEPBOUND may affect the way some medicines work, and some medicines may affect the way ZEPBOUND works.<br/>
                              <content styleCode="bold">Before using ZEPBOUND, tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea which could increase your risk of low blood sugar. Talk to your healthcare provider about low blood sugar levels and how to manage them.</content>
                              <br/>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
</td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">How should I use ZEPBOUND?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Read the <content styleCode="bold">
													Instructions for Use
												</content> that comes with ZEPBOUND.
</item>
                                 <item>Use ZEPBOUND exactly as your healthcare provider tells you to. A healthcare provider should show you how to prepare to inject your dose of ZEPBOUND before injecting the first time.
</item>
                                 <item>Use ZEPBOUND with a reduced-calorie diet and increased physical activity.
</item>
                                 <item>ZEPBOUND is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.
</item>
                                 <item>
                                    <content styleCode="bold">Use ZEPBOUND 1 time each week, at any time of the day.</content>
                                 </item>
                                 <item>You may change the day of the week you use ZEPBOUND as long as the time between the 2 doses is at least <content styleCode="bold">3</content>Â days (72Â hours).
</item>
                                 <item>If you miss a dose of ZEPBOUND, take the missed dose as soon as possible within 4Â days (96Â hours) after the missed dose. If more than 4Â days have passed, skip the missed dose and take your next dose on the regularly scheduled day. <content styleCode="bold">Do not</content> take <content styleCode="bold">2</content> doses of ZEPBOUND within <content styleCode="bold">3</content>Â days (72Â hours) of each other.
</item>
                                 <item>ZEPBOUND may be taken with or without food.
</item>
                                 <item>Change (rotate) your injection site with each weekly injection. You may use the same area of your body but be sure to choose a different injection site in that area. <content styleCode="bold">Do not</content> use the same site for each injection.
</item>
                                 <item>In case of overdose, get medical help or contact a Poison Center expert right away at 1-800-222-1222. Advice is also available online at poisonhelp.org.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the possible side effects of ZEPBOUND?</content>
                              <br/>
                              <content styleCode="bold">ZEPBOUND may cause serious side effects, including:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>See <content styleCode="bold">â<linkHtml href="#p01">What is the most important information I should know about ZEPBOUND?</linkHtml>â</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">severe stomach problems.</content> Stomach problems, sometimes severe, have been reported in people who use ZEPBOUND. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
</item>
                                 <item>
                                    <content styleCode="bold">kidney problems (kidney failure).</content> Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration.
</item>
                                 <item>
                                    <content styleCode="bold">gallbladder problems.</content> Gallbladder problems have happened in some people who use ZEPBOUND. Tell your healthcare provider right away if you get symptoms of gallbladder problems which may include:<table width="100%" styleCode="Noautorules">
                                       <col width="47.600%" align="left"/>
                                       <col width="52.400%" align="left"/>
                                       <tbody>
                                          <tr>
                                             <td align="left" valign="top">
                                                <list listType="unordered" styleCode="Circle">
                                                   <item>pain in your upper stomach (abdomen)
</item>
                                                   <item>fever
</item>
                                                </list>
                                             </td>
                                             <td align="left" valign="top">
                                                <list listType="unordered" styleCode="Circle">
                                                   <item>yellowing of skin or eyes (jaundice)
</item>
                                                   <item>clay-colored stools
</item>
                                                </list>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </item>
                                 <item>
                                    <content styleCode="bold">inflammation of your pancreas (pancreatitis).</content> Stop using ZEPBOUND and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back.
</item>
                                 <item>
                                    <content styleCode="bold">serious allergic reactions.</content> Stop using ZEPBOUND and get medical help right away if you have any symptoms of a serious allergic reaction including: <table width="100%" styleCode="Noautorules">
                                       <col width="47.600%" align="left"/>
                                       <col width="52.400%" align="left"/>
                                       <tbody>
                                          <tr>
                                             <td align="left" valign="top">
                                                <list listType="unordered" styleCode="Circle">
                                                   <item>swelling of your face, lips, tongue or throat
</item>
                                                   <item>problems breathing or swallowing
</item>
                                                   <item>severe rash or itching
</item>
                                                </list>
                                             </td>
                                             <td align="left" valign="top">
                                                <list listType="unordered" styleCode="Circle">
                                                   <item>fainting or feeling dizzy
</item>
                                                   <item>very rapid heartbeat
</item>
                                                </list>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </item>
                                 <item>
                                    <content styleCode="bold">low blood sugar (hypoglycemia).</content> Your risk for getting low blood sugar may be higher if you use ZEPBOUND with medicines that can cause low blood sugar, such as an insulin or sulfonylurea. <content styleCode="bold">Signs and symptoms of low blood sugar may include:</content>
                                    <table width="100%" styleCode="Noautorules">
                                       <col width="35.022%" align="left"/>
                                       <col width="22.126%" align="left"/>
                                       <col width="42.852%" align="left"/>
                                       <tbody>
                                          <tr>
                                             <td align="left" valign="top">
                                                <list listType="unordered" styleCode="Circle">
                                                   <item>dizziness or light-headedness
</item>
                                                   <item>sweating
</item>
                                                   <item>confusion or drowsiness
</item>
                                                   <item>headache
</item>
                                                </list>
                                             </td>
                                             <td align="left" valign="top">
                                                <list listType="unordered" styleCode="Circle">
                                                   <item>blurred vision
</item>
                                                   <item>slurred speech
</item>
                                                   <item>shakiness
</item>
                                                   <item>fast heartbeat
</item>
                                                </list>
                                             </td>
                                             <td align="left" valign="top">
                                                <list listType="unordered" styleCode="Circle">
                                                   <item>anxiety, irritability, or mood changes
</item>
                                                   <item>hunger
</item>
                                                   <item>weakness
</item>
                                                   <item>feeling jittery
</item>
                                                </list>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </item>
                                 <item>
                                    <content styleCode="bold">changes in vision in patients with typeÂ 2 diabetes.</content> Tell your healthcare provider if you have changes in vision during treatment with ZEPBOUND.
</item>
                                 <item>
                                    <content styleCode="bold">depression or thoughts of suicide.</content> You should pay attention to any changes in your mood, behaviors, feelings, or thoughts. Call your healthcare provider right away if you have any changes to your mental health that are new, worse, or worry you.
</item>
                                 <item>
                                    <content styleCode="bold">food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation).</content> ZEPBOUND may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking ZEPBOUND before you are scheduled to have surgery or other procedures.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">The most common side effects of ZEPBOUND include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Lrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>nausea
</item>
                                 <item>diarrhea
</item>
                                 <item>vomiting
</item>
                                 <item>constipation
</item>
                              </list>
                           </td>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>stomach (abdominal) pain
</item>
                                 <item>indigestion
</item>
                                 <item>injection site reactions
</item>
                                 <item>feeling tired
</item>
                              </list>
                           </td>
                           <td align="left" valign="top" styleCode="Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>allergic reactions
</item>
                                 <item>belching
</item>
                                 <item>hair loss
</item>
                                 <item>heartburn
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">Talk to your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of ZEPBOUND. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
</td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I store ZEPBOUND?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store ZEPBOUND in the refrigerator between 36Â°F to 46Â°F (2Â°C to 8Â°C). Store ZEPBOUND in the original carton until use to protect it from light.
</item>
                                 <item>If needed, each single-dose pen or single-dose vial can be stored at room temperature up to 86Â°F (30Â°C) for up to 21Â days. If ZEPBOUND is stored at room temperature, it should not be returned to the refrigerator.
</item>
                                 <item>Discard if not used within 21Â days after removing from the refrigerator.
</item>
                                 <item>Do not freeze ZEPBOUND. Do not use ZEPBOUND if frozen.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Keep ZEPBOUND and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of ZEPBOUND.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ZEPBOUND for a condition for which it was not prescribed. Do not give ZEPBOUND to other people, even if they have the same condition you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ZEPBOUND that is written for health professionals.
</td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in ZEPBOUND?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> tirzepatide<br/>
                              <content styleCode="bold">Inactive ingredients:</content> sodium chloride, sodium phosphate dibasic heptahydrate, and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH.<br/>ZEPBOUND<sup>Â®</sup> is a registered trademark of Eli Lilly and Company.<br/>
                              <content styleCode="bold">Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA</content>
                              <br/>Copyright Â© 2023, 2024, Eli Lilly and Company. All rights reserved.<br/>For more information, go to www.zepbound.com or call 1-800-545-5979.
</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>ZEP-0004-MG-20241220
</paragraph>
               </text>
               <effectiveTime value="20241220"/>
            </section>
         </component>
         <component>
            <section ID="s121">
               <id root="0976d3fc-19cb-4907-9087-3f65f15cb0a3"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>SINGLE-DOSE PEN INSTRUCTIONS FOR USE
</title>
               <text>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="justify"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="bottom">
                              <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                              <br/>
                              <content styleCode="bold">ZEPBOUND<sup>TM</sup> (ZEHP-bownd)</content>
                              <br/>
                              <content styleCode="bold">(tirzepatide)</content>
                              <br/>
                              <content styleCode="bold">injection, for subcutaneous use</content>
                              <br/>
                              <br/>
                              <renderMultiMedia ID="f06" referencedObject="mm06"/>
                              <br/>
                              <br/>
                              <br/>
                              <content styleCode="bold">2.5Â mg/0.5Â mL single-dose pen</content>
                              <br/>
                              <content styleCode="bold">5Â mg/0.5Â mL single-dose pen</content>
                              <br/>
                              <content styleCode="bold">7.5Â mg/0.5Â mL single-dose pen</content>
                              <br/>
                              <content styleCode="bold">10Â mg/0.5Â mL single-dose pen</content>
                              <br/>
                              <content styleCode="bold">12.5Â mg/0.5Â mL single-dose pen</content>
                              <br/>
                              <content styleCode="bold">15Â mg/0.5Â mL single-dose pen</content>
                              <br/>
                              <content styleCode="bold">use 1 time each week</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Important information you need to know before injecting ZEPBOUND</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Read this Instructions for Use and the Medication Guide before using your ZEPBOUND pen and each time you get a refill.</content> There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.
</paragraph>
                  <paragraph>Talk to your healthcare provider about how to inject ZEPBOUND the right way.
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>ZEPBOUND is a single-dose prefilled pen.
</item>
                     <item>ZEPBOUND is used 1 time each week.
</item>
                     <item>Inject under the skin (subcutaneously) only.
</item>
                     <item>You or another person can inject into your stomach (abdomen) or thigh.
</item>
                     <item>Another person can inject into the back of your upper arm.
</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Guide to parts</content>
                  </paragraph>
                  <renderMultiMedia ID="f07" referencedObject="mm07"/>
                  <paragraph>
                     <content styleCode="bold">Preparing to inject ZEPBOUND</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="14.133%" align="left"/>
                     <col width="10.833%" align="left"/>
                     <col width="75.033%" align="left"/>
                     <tbody>
                        <tr>
                           <td colspan="3" align="left" valign="middle">
                              <content styleCode="bold">Remove the pen</content> from the refrigerator.<br/>Leave the gray base cap on until you are ready to inject.
</td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="middle">
                              <content styleCode="bold">Check the pen</content> label to make sure you have the right medicine and dose, and that it has not expired.<br/>
                              <content styleCode="bold">Inspect the pen</content> to make sure that it is not damaged.
</td>
                           <td align="left" valign="middle">
                              <br/>
                              <renderMultiMedia ID="f08" referencedObject="mm08"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="middle">Make sure the medicine:
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="middle">
                              <list listType="unordered" styleCode="Disc">
                                 <item>is not frozen
</item>
                                 <item>is not cloudy
</item>
                              </list>
                           </td>
                           <td colspan="2" align="left" valign="middle">
                              <list listType="unordered" styleCode="Disc">
                                 <item>is colorless to slightly yellow
</item>
                                 <item>does not have particles
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="middle">
                              <content styleCode="bold">Wash your hands.</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="15.850%" align="left"/>
                     <col width="84.150%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="top">
                              <content styleCode="bold">Step</content>
                              <br/>
                              <content styleCode="bold">1</content>
                           </td>
                           <td align="left" valign="middle">
                              <content styleCode="bold">Choose your injection site</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top">
                              <br/>
                              <renderMultiMedia ID="f09" referencedObject="mm09"/>
                           </td>
                           <td align="left" valign="top">Your healthcare provider can help you choose the injection site that is best for you.<br/>
                              <br/>You or another person can inject the medicine in your stomach (abdomen) or thigh.
</td>
                        </tr>
                        <tr>
                           <td align="center" valign="top">
                              <br/>
                              <renderMultiMedia ID="f10" referencedObject="mm10"/>
                           </td>
                           <td align="left" valign="top">Another person should give you the injection in the back of your upper arm.<br/>Change (rotate) your injection site each week.<br/>You may use the same area of your body but be sure to choose a different injection site in that area.
</td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="10.800%" align="left"/>
                     <col width="18.933%" align="left"/>
                     <col width="70.267%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Step</content>
                              <br/>
                              <content styleCode="bold">Â Â Â 2</content>
                           </td>
                           <td colspan="2" align="left" valign="middle">
                              <content styleCode="bold">Pull off the gray base cap</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" rowspan="2" align="left" valign="top">
                              <br/>
                              <renderMultiMedia ID="f11" referencedObject="mm11"/>
                           </td>
                           <td align="left" valign="top">Make sure the pen is <content styleCode="bold">locked</content>.<br/>
                              <content styleCode="bold">Do not</content> unlock the pen until you place the clear base on your skin and are ready to inject.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="bottom">
                              <content styleCode="bold">Pull</content> the gray base cap straight off and throw it away in your household trash.<br/>
                              <content styleCode="bold">Do not</content> put the gray base cap back on â this could damage the needle.<br/>
                              <content styleCode="bold">Do not</content> touch the needle.
</td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="15.067%" align="left"/>
                     <col width="9.733%" align="left"/>
                     <col width="75.200%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Step</content>
                              <br/>
                              <content styleCode="bold">Â Â Â 3</content>
                           </td>
                           <td colspan="2" align="left" valign="middle">
                              <content styleCode="bold">Place clear base on skin, then unlock</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top"/>
                           <td colspan="2" align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td colspan="2" align="center" valign="middle">
                              <br/>
                              <renderMultiMedia ID="f12" referencedObject="mm12"/>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">Place</content> the clear base flat against your skin at the injection site.
</td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center" valign="top">
                              <br/>
                              <renderMultiMedia ID="f13" referencedObject="mm13"/>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">Unlock</content> by turning the lock ring.
</td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="10.800%" align="left"/>
                     <col width="10.000%" align="left"/>
                     <col width="79.200%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <paragraph ID="p03">
                                 <content styleCode="bold">Step</content>
                                 <br/>
                                 <content styleCode="bold">Â Â Â 4</content>
                              </paragraph>
                           </td>
                           <td colspan="2" align="left" valign="middle">
                              <content styleCode="bold">Press and hold up to 10 seconds</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center" valign="middle">
                              <br/>
                              <renderMultiMedia ID="f14" referencedObject="mm14"/>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">Press and hold</content> the purple injection button for up to 10 seconds.<br/>
                              <content styleCode="bold">Listen</content> for:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>First click = injection started
</item>
                                 <item>Second click = injection completed
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" rowspan="2" align="center" valign="middle">
                              <br/>
                              <renderMultiMedia ID="f15" referencedObject="mm15"/>
                           </td>
                           <td align="left" valign="middle">You will know your injection is complete when the gray plunger is visible.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="middle"/>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">After your injection, place the used pen in a sharps container.</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">See <content styleCode="bold">
                                 <linkHtml href="#p02">Disposing of your used pen</linkHtml>.</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="p02">
                     <content styleCode="bold">Disposing of your used pen</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Put your used pen in an FDA-cleared sharps disposal container right away after use. <content styleCode="bold">Do not</content> throw away (dispose of) pens in your household trash.
</item>
                     <item>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:<list listType="unordered" styleCode="Disc">
                           <item>
                              <caption>-
</caption>made of a heavy-duty plastic,
</item>
                           <item>
                              <caption>-
</caption>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
</item>
                           <item>
                              <caption>-
</caption>upright and stable during use,
</item>
                           <item>
                              <caption>-
</caption>leak-resistant, and
</item>
                           <item>
                              <caption>-
</caption>properly labeled to warn of hazardous waste inside the container.
</item>
                        </list>
                     </item>
                     <item>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.
</item>
                     <item>
                        <content styleCode="bold">Do not</content> recycle your used sharps disposal container.
</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Storage and handling</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Store your pen in the refrigerator between 36Â°F to 46Â°F (2Â°C to 8Â°C).
</item>
                     <item>You may store your pen at room temperature up to 86Â°F (30Â°C) for up to 21 days. If you store the pen at room temperature, do not return the pen to the refrigerator.
</item>
                     <item>Discard the pen if not used within 21 days after removing from the refrigerator.
</item>
                     <item>
                        <content styleCode="bold">Do not</content> freeze your pen. If the pen has been frozen, throw the pen away and use a new pen.
</item>
                     <item>Store your pen in the original carton to protect your pen from light.
</item>
                     <item>The pen has glass parts. Handle it carefully. If you drop the pen on a hard surface, <content styleCode="bold">do not</content> use it. Use a new pen for your injection.
</item>
                     <item>Keep your ZEPBOUND pen and all medicines out of the reach of children.
</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Commonly asked questions</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What if I see air bubbles in my pen?</content>
                  </paragraph>
                  <paragraph>Air bubbles are normal.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">What if my pen is not at room temperature?</content>
                  </paragraph>
                  <paragraph>It is not necessary to warm the pen to room temperature.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">What if I unlock the pen and press the purple injection button before pulling off the gray base cap?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not</content> remove the gray base cap. Throw away the pen and get a new pen.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">What if there is a drop of liquid on the tip of the needle when I remove the gray base cap?</content>
                  </paragraph>
                  <paragraph>A drop of liquid on the tip of the needle is normal. <content styleCode="bold">Do not</content> touch the needle.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do I need to hold the injection button down until the injection is complete?</content>
                  </paragraph>
                  <paragraph>This is not necessary, but it may help you keep the pen steady against your skin.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">I heard more than 2 clicks during my injectionâ2 loud clicks and 1 soft one. Did I get my complete injection?</content>
                  </paragraph>
                  <paragraph>Some people may hear a soft click right before the second loud click. That is the normal operation of the pen. <content styleCode="bold">Do not</content> remove the pen from your skin until you hear the second loud click.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">I am not sure if my pen worked the right way.</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="19.150%" align="left"/>
                     <col width="80.850%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <br/>
                              <renderMultiMedia ID="f16" referencedObject="mm16"/>
                           </td>
                           <td align="left" valign="top">Check to see if you have received your dose. Your dose was delivered the right way if the gray plunger is visible. Also, see <content styleCode="bold">
                                 <linkHtml href="#p03">Step 4</linkHtml>
                              </content> of the instructions.<br/>If you do not see the gray plunger, contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) for further instructions. Until then, store your pen safely to avoid an accidental needle stick.<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">What if there is a drop of liquid or blood on my skin after my injection?</content>
                  </paragraph>
                  <paragraph>This is normal. Press a cotton ball or gauze over the injection site. <content styleCode="bold">Do not</content> rub the injection site.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Other information</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>If you have vision problems, <content styleCode="bold">do not</content> use your pen without help from a person trained to use the ZEPBOUND pen.
</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Where to learn more</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>If you have questions or problems with your ZEPBOUND pen, contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) or call your healthcare provider.
</item>
                     <item>For more information about the ZEPBOUND pen, visit our website at www.zepbound.com.
</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="14.167%" align="left"/>
                     <col width="36.667%" align="left"/>
                     <col width="49.167%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <br/>
                              <renderMultiMedia ID="f17" referencedObject="mm17"/>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">Scan this code to launch <br/>www.zepbound.com</content>
                           </td>
                           <td align="left" valign="top"/>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Marketed by:<br/>Lilly USA, LLC<br/>Indianapolis, IN 46285, USA
</paragraph>
                  <paragraph>ZEPBOUND is a trademark of Eli Lilly and Company.
</paragraph>
                  <paragraph>Copyright Â© 2023, Eli Lilly and Company. All rights reserved.
</paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration. Revised: November 2023
</paragraph>
                  <paragraph>ZEP-0002-PEN-IFU-20231109
</paragraph>
                  <paragraph>
                     <renderMultiMedia ID="f18" referencedObject="mm18"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240523"/>
               <component>
                  <observationMedia ID="mm06">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-pen-ifu-1-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm07">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-pen-ifu-2-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm08">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-pen-ifu-3-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm09">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-pen-ifu-4a-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm10">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-pen-ifu-4b-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm11">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-pen-ifu-5-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm12">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-pen-ifu-6-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm13">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-pen-ifu-7-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm14">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-pen-ifu-8-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm15">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-pen-ifu-9-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm16">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-pen-ifu-10-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm17">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-qr.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm18">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="logo.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s122">
               <id root="be93d9fc-15ae-422b-b2a3-393dff85b742"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>SINGLE-DOSE VIAL INSTRUCTIONS FOR USE
</title>
               <text>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="justify" valign="bottom">
                              <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                              <br/>
                              <content styleCode="bold">ZEPBOUND<sup>Â®</sup> [ZEHP-bownd]</content>
                              <br/>
                              <content styleCode="bold">(tirzepatide)</content>
                              <br/>
                              <content styleCode="bold">injection, for subcutaneous use</content>
                              <br/>
                              <br/>
                              <content styleCode="bold">2.5Â mg/0.5Â mL single-dose vial</content>
                              <br/>
                              <content styleCode="bold">5Â mg/0.5Â mL single-dose vial</content>
                              <br/>
                              <content styleCode="bold">7.5Â mg/0.5Â mL single-dose vial</content>
                              <br/>
                              <content styleCode="bold">10Â mg/0.5Â mL single-dose vial</content>
                              <br/>
                              <content styleCode="bold">12.5Â mg/0.5Â mL single-dose vial</content>
                              <br/>
                              <content styleCode="bold">15Â mg/0.5Â mL single-dose vial</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Important information you need to know before injecting ZEPBOUND</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Read this Instructions for Use before you start taking ZEPBOUND and each time you get a new vial.</content> There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.						
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not share your needles or syringes with other people. You may give other people a serious infection or get a serious infection from them.</content>
                  </paragraph>
                  <paragraph>Talk to your healthcare provider about how to inject ZEPBOUND the right way.
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>ZEPBOUND is a single-dose vial.
</item>
                     <item>ZEPBOUND is used 1 time each week.
</item>
                     <item>Inject under the skin (subcutaneously) only.
</item>
                     <item>You or another person may inject into your stomach (abdomen) or thigh.
</item>
                     <item>Another person can inject into the back of your upper arm.
</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Gather supplies needed to give your injection</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>1 single-dose ZEPBOUND vial
</item>
                     <item>1 syringe and 1 needle, supplied separately (for example, use a 1 mL syringe and needle as recommended by your healthcare provider)
</item>
                     <item>1 alcohol swab
</item>
                     <item>gauze
</item>
                     <item>1 sharps container for throwing away used needles and syringes. <content styleCode="bold">See</content> âDisposing of used needles and syringesâ at the end of these instructions.
</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="20.000%" align="left"/>
                     <col width="80.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="middle">
                              <content styleCode="bold">Guide to parts<br/>
                                 <br/>Vial</content>
                           </td>
                           <td align="center" valign="middle">
                              <content styleCode="bold">Needle and Syringe (not included)</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="middle">
                              <renderMultiMedia ID="f34a" referencedObject="mm34a"/>
                           </td>
                           <td align="center" valign="middle">
                              <renderMultiMedia ID="f34b" referencedObject="mm34b"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Note:</content> The needle and syringe are not included. The needle and syringe recommended by your healthcare provider may look different than the needle and syringe in this Instructions for Use.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Preparing to inject ZEPBOUND</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Remove the vial</content>  from the refrigerator.						
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Check the vial</content> label to make sure you have the right medicine and dose, and that it has not expired.						
</paragraph>
                  <paragraph>Make sure the medicine:
</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="50%" align="left"/>
                     <col width="50%" align="left"/>
                     <tbody>
                        <tr>
                           <td>
                              <list listType="unordered" styleCode="Disc">
                                 <item>is not frozen
</item>
                                 <item>is not cloudy
</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Disc">
                                 <item>is colorless to slightly yellow
</item>
                                 <item>does not have particles
</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Always use a new syringe and needle for each injection to prevent infections and blocked needles. Do not reuse or share your syringes or needles with other people. You may give other people a serious infection or get a serious infection from them.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Wash your hands with soap and water.</content>
                  </paragraph>
                  <table width="100%">
                     <col width="53.250%" align="left"/>
                     <col width="46.750%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Step 1:</content>
                              <br/>Pull off the plastic protective cap. <content styleCode="bold">Do not</content> remove the rubber stopper.
</td>
                           <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                              <renderMultiMedia ID="f35" referencedObject="mm35"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 2:</content>
                              <br/>Wipe the rubber stopper with an alcohol swab.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f36" referencedObject="mm36"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 3:</content>
                              <br/>Remove the outer wrapping from the syringe.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f37" referencedObject="mm37"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 4:</content>
                              <br/>Remove the outer wrapping from the needle.<br/>The syringe that your healthcare provider recommended may have a pre-attached needle. If the needle is attached, skip to step 6.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f38" referencedObject="mm38"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 5:</content>
                              <br/>Place the needle on top of the syringe and turn until it is tight and firmly attached.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f39" referencedObject="mm39"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 6:</content>
                              <br/>Remove the needle shield by pulling straight off.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f40" referencedObject="mm40"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 7:</content>
                              <br/>Hold the syringe in one hand with the needle pointing up. With the other hand pull down on the plunger until the plunger tip reaches the line on the syringe indicating that 0.5Â mL of air has been drawn into the syringe.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f41" referencedObject="mm41"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 8:</content>
                              <br/>Push the needle through the rubber stopper of the vial.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <br/>
                              <renderMultiMedia ID="f42" referencedObject="mm42"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 9:</content>
                              <br/>Push the plunger all the way in. This puts air into the vial and makes it easier to pull the solution from the vial.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <br/>
                              <renderMultiMedia ID="f43" referencedObject="mm43"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Step 10: </content>
                              <br/>Turn the vial and syringe upside down. Make sure that the tip of the needle is in the liquid and slowly pull the plunger down until the plunger tip is past the 0.5 mL line.<br/> If there are air bubbles, tap the syringe gently a few times to let any air bubbles rise to the top.
</td>
                           <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                              <renderMultiMedia ID="f44" referencedObject="mm44"/>
                              <renderMultiMedia ID="f45" referencedObject="mm45"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 11:</content>
                              <br/>Slowly push the plunger up until the plunger tip reaches the 0.5 mL line.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f46" referencedObject="mm46"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 12:</content>
                              <br/>Pull the syringe out of the rubber stopper of the vial.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f47" referencedObject="mm47"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Injecting ZEPBOUND </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Inject exactly as your healthcare provider has shown you. Your healthcare provider should tell you if you should pinch the skin before injecting.
</item>
                     <item>
                        <content styleCode="bold">Change (rotate) your injection site within the area you choose for each dose</content> to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.
</item>
                     <item>
                        <content styleCode="bold">Do not</content> inject where the skin has pits, is thickened, or has lumps.
</item>
                     <item>
                        <content styleCode="bold">Do not</content> inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.
</item>
                     <item>
                        <content styleCode="bold">Do not</content> mix ZEPBOUND with any other medicine.
</item>
                     <item>
                        <content styleCode="bold">Do not</content> inject ZEPBOUND in the same injection site used for other medicines.
</item>
                  </list>
                  <table width="100%">
                     <col width="53.250%" align="left"/>
                     <col width="46.750%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Step 13: </content>
                              <br/>Choose your injection site.	<br/> You can inject ZEPBOUND under the skin (subcutaneously) of your stomach area (abdomen) or thighs.	<br/> Someone else can inject in your stomach area, thighs, or the back of the upper arms.
</td>
                           <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                              <renderMultiMedia ID="f48" referencedObject="mm48"/>
                              <renderMultiMedia ID="f49" referencedObject="mm49"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 14:</content>
                              <br/>Insert the needle into your skin.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f50" referencedObject="mm50"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 15:</content>
                              <br/>Push down on the plunger to inject your dose.										<br/>The needle should stay in your skin for at least 5 seconds to make sure you have injected all of your dose.
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f51" referencedObject="mm51"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Step 16:</content>
                              <br/>Pull the needle out of your skin.<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>If you see blood after you take the needle out of your skin, press the injection site with a piece of gauze or an alcohol swab. <content styleCode="bold">Do not</content> rub the area.
</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> recap the needle. Recapping the needle can lead to a needle stick injury.
</item>
                              </list>
                           </td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">
                              <renderMultiMedia ID="f52" referencedObject="mm52"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Disposing of used needles and syringes</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Put your used needle and syringe in an FDA-cleared sharps disposal container right away after use. <content styleCode="bold">Do not</content> throw away (dispose of) loose needles and syringes in your household trash.
</item>
                     <item>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:							<list listType="unordered">
                           <item>
                              <caption>-
</caption> made of a heavy-duty plastic,
</item>
                           <item>
                              <caption>-
</caption> can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
</item>
                           <item>
                              <caption>-
</caption> upright and stable during use,
</item>
                           <item>
                              <caption>-
</caption> leak-resistant, and
</item>
                           <item>
                              <caption>-
</caption> properly labeled to warn of hazardous waste inside the container.
</item>
                        </list>
                     </item>
                     <item>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDAâs website at: <br/>	http://www.fda.gov/safesharpsdisposal.
</item>
                     <item>
                        <content styleCode="bold">Do not</content> dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. <content styleCode="bold">Do not</content> recycle your used sharps disposal container.
</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Storing ZEPBOUND</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Store all unopened vials in the refrigerator at 36Â°F to 46Â°F (2Â°C to 8Â°C).
</item>
                     <item>You may store the unopened vial at room temperature up to 86Â°F (30Â°C) for up to 21 days.
</item>
                     <item>
                        <content styleCode="bold">Do not</content> freeze. <content styleCode="bold">Do not</content> use if ZEPBOUND has been frozen.
</item>
                     <item>Store the vial in the original carton to protect from light.
</item>
                     <item>Throw away all opened vials after use, even if there is medicine left in the vial.
</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep ZEPBOUND vials, syringes, needles, and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>If you have any questions or problems with your ZEPBOUND, contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) or call your healthcare provider for help.
</paragraph>
                  <paragraph>							Marketed by:<br/> Lilly USA, LLC <br/> Indianapolis, IN 46285, USA						
</paragraph>
                  <paragraph>ZEPBOUND is a registered trademark of Eli Lilly and Company.
</paragraph>
                  <paragraph>Copyright Â© 2024, Eli Lilly and Company. All rights reserved.
</paragraph>
                  <paragraph>ZEP-0001-VL-IFU-20240328
</paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.
</paragraph>
                  <paragraph>Issued: March 2024
</paragraph>
               </text>
               <effectiveTime value="20240328"/>
               <component>
                  <observationMedia ID="mm34a">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-vial-ifu-1-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm34b">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-vial-ifu-2-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm35">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-vial-ifu-3-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm36">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-vial-ifu-4-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm37">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-vial-ifu-5-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm38">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-vial-ifu-6-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm39">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-vial-ifu-7-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm40">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-vial-ifu-8-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm41">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-vial-ifu-9-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm42">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-vial-ifu-10-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm43">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-vial-ifu-11-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm44">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-vial-ifu-12-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm45">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-vial-ifu-13-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm46">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-vial-ifu-14-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm47">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-vial-ifu-15-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm48">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-vial-ifu-16-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm49">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-vial-ifu-17-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm50">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-vial-ifu-18-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm51">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-vial-ifu-19-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm52">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-vial-ifu-20-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s123">
               <id root="22251dd4-86ba-41b2-93a3-216aaf494f83"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Zepbound<sup>TM</sup>, 2.5 mg/0.5 mL, Carton, 4 Single-Dose Pens</content>
                  </paragraph>
                  <paragraph>NDC 0002-2506-80
</paragraph>
                  <paragraph>Zepbound<sup>TM</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>2.5 mg/0.5 mL
</paragraph>
                  <paragraph>4 x 2.5 mg/0.5 mL prefilled pens
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Use one pen every week.
</paragraph>
                  <paragraph>4 Single-dose prefilled pens
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f19" referencedObject="mm19"/>
               </text>
               <effectiveTime value="20240328"/>
               <component>
                  <observationMedia ID="mm19">
                     <text>PACKAGE LABEL - Zepbound, 2.5 mg/0.5 mL, Carton, 4 Single-Dose Pens
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-carton-2pt5mg-pen-088-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s124">
               <id root="d35c720a-dcb3-4a73-a919-798fd9583fae"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Zepbound<sup>TM</sup>, 5 mg/0.5 mL, Carton, 4 Single-Dose Pens</content>
                  </paragraph>
                  <paragraph>NDC 0002-2495-80
</paragraph>
                  <paragraph>Zepbound<sup>TM</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>5 mg/0.5 mL
</paragraph>
                  <paragraph>4 x 5 mg/0.5 mL prefilled pens
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Use one pen every week.
</paragraph>
                  <paragraph>4 Single-dose prefilled pens
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f20" referencedObject="mm20"/>
               </text>
               <effectiveTime value="20240328"/>
               <component>
                  <observationMedia ID="mm20">
                     <text>PACKAGE LABEL - Zepbound, 5 mg/0.5 mL, Carton, 4 Single-Dose Pens
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-carton-5mg-pen-089-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s125">
               <id root="1ba82f7f-8cf4-49d0-877c-b9d618a23ae4"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Zepbound<sup>TM</sup>, 7.5 mg/0.5 mL, Carton, 4 Single-Dose Pens</content>
                  </paragraph>
                  <paragraph>NDC 0002-2484-80
</paragraph>
                  <paragraph>Zepbound<sup>TM</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>7.5 mg/0.5 mL
</paragraph>
                  <paragraph>4 x 7.5 mg/0.5 mL prefilled pens
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Use one pen every week.
</paragraph>
                  <paragraph>4 Single-dose prefilled pens
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f21" referencedObject="mm21"/>
               </text>
               <effectiveTime value="20240328"/>
               <component>
                  <observationMedia ID="mm21">
                     <text>PACKAGE LABEL - Zepbound, 7.5 mg/0.5 mL, Carton, 4 Single-Dose Pens
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-carton-7pt5mg-pen-090-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s126">
               <id root="4a06b85d-e9a3-4825-a0a5-fd14daeaed7b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Zepbound<sup>TM</sup>, 10 mg/0.5 mL, Carton, 4 Single-Dose Pens</content>
                  </paragraph>
                  <paragraph>NDC 0002-2471-80
</paragraph>
                  <paragraph>Zepbound<sup>TM</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>10 mg/0.5 mL
</paragraph>
                  <paragraph>4 x 10 mg/0.5 mL prefilled pens
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Use one pen every week.
</paragraph>
                  <paragraph>4 Single-dose prefilled pens
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f22" referencedObject="mm22"/>
               </text>
               <effectiveTime value="20240328"/>
               <component>
                  <observationMedia ID="mm22">
                     <text>PACKAGE LABEL - Zepbound, 10 mg/0.5 mL, Carton, 4 Single-Dose Pens
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-carton-10mg-pen-091-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s127">
               <id root="f7f3fc5b-10cb-4b18-8971-879cbd9f43ed"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Zepbound<sup>TM</sup>, 12.5 mg/0.5 mL, Carton, 4 Single-Dose Pens</content>
                  </paragraph>
                  <paragraph>NDC 0002-2460-80
</paragraph>
                  <paragraph>Zepbound<sup>TM</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>12.5 mg/0.5 mL
</paragraph>
                  <paragraph>4 x 12.5 mg/0.5 mL prefilled pens
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Use one pen every week.
</paragraph>
                  <paragraph>4 Single-dose prefilled pens
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f23" referencedObject="mm23"/>
               </text>
               <effectiveTime value="20240328"/>
               <component>
                  <observationMedia ID="mm23">
                     <text>PACKAGE LABEL - Zepbound, 12.5 mg/0.5 mL, Carton, 4 Single-Dose Pens
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-carton-12pt5mg-pen-092-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s128">
               <id root="8c5c7b98-1689-476d-a9aa-b4c487b2b8e0"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Zepbound<sup>TM</sup>, 15 mg/0.5 mL, Carton, 4 Single-Dose Pens</content>
                  </paragraph>
                  <paragraph>NDC 0002-2457-80
</paragraph>
                  <paragraph>Zepbound<sup>TM</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>15 mg/0.5 mL
</paragraph>
                  <paragraph>4 x 15 mg/0.5 mL prefilled pens
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Use one pen every week.
</paragraph>
                  <paragraph>4 Single-dose prefilled pens
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f24" referencedObject="mm24"/>
               </text>
               <effectiveTime value="20240328"/>
               <component>
                  <observationMedia ID="mm24">
                     <text>PACKAGE LABEL - Zepbound, 15 mg/0.5 mL, Carton, 4 Single-Dose Pens
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-carton-15mg-pen-093-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s129">
               <id root="0fbe78ec-3ae6-4e73-b581-17e5a29de952"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Zepbound<sup>Â®</sup>, 2.5 mg/0.5 mL, Carton, 4 Single-dose Vials</content>
                  </paragraph>
                  <paragraph>NDC 0002-0152-04
</paragraph>
                  <paragraph>Zepbound<sup>Â®</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>2.5 mg/0.5 mL
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Needles and Syringes are not included
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Use one vial every week.
</paragraph>
                  <paragraph>4 Single-dose vials
</paragraph>
                  <paragraph>Discard unused portion</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f28" referencedObject="mm28"/>
                  <renderMultiMedia ID="f53" referencedObject="mm53"/>
               </text>
               <effectiveTime value="20250312"/>
               <component>
                  <observationMedia ID="mm28">
                     <text>PACKAGE LABEL - Zepbound, 2.5 mg/0.5 mL, 4 count Single-dose Vials
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-carton-2pt5mg-vial-p-008-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm53">
                     <text>PACKAGE LABEL - Zepbound, 2.5 mg/0.5 mL, 4 count Single-dose Vials
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-carton-2pt5mg-vial-r-004-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s130">
               <id root="dc1fd5be-f065-4ac7-af8c-1c5566a86422"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Zepbound<sup>Â®</sup>, 5 mg/0.5 mL, Carton, 4 Single-dose Vials</content>
                  </paragraph>
                  <paragraph>NDC 0002-0243-04
</paragraph>
                  <paragraph>Zepbound<sup>Â®</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>5 mg/0.5 mL
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Needles and Syringes are not included
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Use one vial every week.
</paragraph>
                  <paragraph>4 Single-dose vials
</paragraph>
                  <paragraph>Discard unused portion
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f29" referencedObject="mm29"/>
                  <renderMultiMedia ID="f54" referencedObject="mm54"/>
               </text>
               <effectiveTime value="20250312"/>
               <component>
                  <observationMedia ID="mm29">
                     <text>PACKAGE LABEL - Zepbound, 5 mg/0.5 mL, 4 count Single-dose Vials
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-carton-5mg-vial-p-009-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm54">
                     <text>PACKAGE LABEL - Zepbound, 5 mg/0.5 mL, 4 count Single-dose Vials
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-carton-5mg-vial-r-005-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s131">
               <id root="2ddfb6c7-c1d9-4134-9b8e-af41d0be98b9"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Zepbound<sup>Â®</sup>, 7.5 mg/0.5 mL, Carton, 4 Single-dose Vials</content>
                  </paragraph>
                  <paragraph>NDC 0002-1214-04
</paragraph>
                  <paragraph>Zepbound<sup>Â®</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>7.5 mg/0.5 mL
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Needles and Syringes are not included
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Use one vial every week.</paragraph>
                  <paragraph>4 Single-dose vials
</paragraph>
                  <paragraph>Discard unused portion
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f30" referencedObject="mm30"/>
                  <renderMultiMedia ID="f30a" referencedObject="mm30a"/>
               </text>
               <effectiveTime value="20250312"/>
               <component>
                  <observationMedia ID="mm30">
                     <text>PACKAGE LABEL - Zepbound, 7.5 mg/0.5 mL, 4 count Single-dose Vials
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-carton-7pt5mg-vial-p-022-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm30a">
                     <text>PACKAGE LABEL - Zepbound, 7.5 mg/0.5 mL, 4 count Single-dose Vials
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-carton-7pt5mg-vial-r-025-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s132">
               <id root="54da751c-5fc5-4dc6-bfe9-317b0ac5c6e4"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Zepbound<sup>Â®</sup>, 10 mg/0.5 mL, Carton, 4 Single-dose Vials</content>
                  </paragraph>
                  <paragraph>NDC 0002-1340-04
</paragraph>
                  <paragraph>Zepbound<sup>Â®</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>10 mg/0.5 mL
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Needles and Syringes are not included
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Use one vial every week.</paragraph>
                  <paragraph>4 Single-dose vials
</paragraph>
                  <paragraph>Discard unused portion
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f31" referencedObject="mm31"/>
                  <renderMultiMedia ID="f31a" referencedObject="mm31a"/>
               </text>
               <effectiveTime value="20250312"/>
               <component>
                  <observationMedia ID="mm31">
                     <text>PACKAGE LABEL - Zepbound, 10 mg/0.5 mL, 4 count Single-dose Vials
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-carton-10mg-vial-p-023-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm31a">
                     <text>PACKAGE LABEL - Zepbound, 10 mg/0.5 mL, 4 count Single-dose Vials
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-carton-10mg-vial-r-026-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s133">
               <id root="946b4dd2-6f78-46af-a238-3bbfa7a8bace"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Zepbound<sup>Â®</sup>, 12.5 mg/0.5 mL, Carton, Single-dose Vial</content>
                  </paragraph>
                  <paragraph>NDC 0002-1423-01
</paragraph>
                  <paragraph>Zepbound<sup>Â®</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>12.5 mg/0.5 mL
</paragraph>
                  <paragraph>Single-dose Vial - discard unused portion
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Needles and Syringes are not included
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f32" referencedObject="mm32"/>
               </text>
               <effectiveTime value="20250312"/>
               <component>
                  <observationMedia ID="mm32">
                     <text>PACKAGE LABEL - Zepbound, 12.5 mg/0.5 mL, Single-dose Vial
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-carton-12pt5mg-vial-nl006.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s134">
               <id root="9d9397e2-cde7-44b1-b3d1-6fa98433bc67"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - Zepbound<sup>Â®</sup>, 15 mg/0.5 mL, Carton, Single-dose Vial</content>
                  </paragraph>
                  <paragraph>NDC 0002-2002-01
</paragraph>
                  <paragraph>Zepbound<sup>Â®</sup>
                  </paragraph>
                  <paragraph>(tirzepatide) injection
</paragraph>
                  <paragraph>15 mg/0.5 mL
</paragraph>
                  <paragraph>Single-dose Vial - discard unused portion
</paragraph>
                  <paragraph>Rx Only
</paragraph>
                  <paragraph>For Subcutaneous Use
</paragraph>
                  <paragraph>Needles and Syringes are not included
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f33" referencedObject="mm33"/>
               </text>
               <effectiveTime value="20250312"/>
               <component>
                  <observationMedia ID="mm33">
                     <text>PACKAGE LABEL - Zepbound, 15 mg/0.5 mL, Single-dose Vial
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zep-carton-15mg-vial-nl007.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>